

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
16 August 2001 (16.08.2001)

PCT

(10) International Publication Number
WO 01/59092 A2

(51) International Patent Classification: C12N 15/00

Way, Baltimore, MA 21208 (US). KINZLER, Kenneth, W. [US/US]; 1403 Halkirk Way, BelAir, MD 21015 (US).

(21) International Application Number: PCT/US01/04339

(22) International Filing Date: 12 February 2001 (12.02.2001)

(74) Agents: KAGAN, Sarah, A. et al.; Banner & Witcoff, Ltd., Eleven floor, 1001 G Street, N.W., Washington, DC 20001-4597 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/181,929 11 February 2000 (11.02.2000) US

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/181,929 (CON)
Filed on 11 February 2000 (11.02.2000)

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): THE
JOHNS HOPKINS UNIVERSITY [US/US]; 111 Market
Place, Suite 906, Baltimore, MD 21202 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NICOLAIDES,
Nicholas, C. [US/US]; 4 Cider Mill Court, Boothwyn,
PA 19061 (US). SASS, Philip, M. [US/US]; 1903 Black-
hawk Circle, Audubon, PA 19403 (US). GRASSO, Luigi
[US/US]; 834 Chestnut Street, Apt. #816, Philadelphia, PA
19107 (US). VOGELSTEIN, Bert [US/US]; 3700 Breton

Published:

— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR GENERATING HYPERMUTABLE MICROBES

(57) Abstract: Bacteria are manipulated to create desirable output traits using dominant negative alleles of mismatch repair proteins. Enhanced hypermutation is achieved by combination of mismatch repair deficiency and exogenously applied mutagens. Stable bacteria containing desirable output traits are obtained by restoring mismatch repair activity to the bacteria.

WO 01/59092 A2

METHODS FOR GENERATING HYPERMUTABLE MICROBES

- 5 This application claims the benefit of provisional application S.N.
60/181,929 filed February 11, 2000.

FIELD OF THE INVENTION

- 10 The invention is related to the area of mismatch repair genes. In
particular it is related to the field of *in situ* mutagenesis of single celled
organisms.

BACKGROUND OF THE INVENTION

- Within the past four years, the genetic cause of the Hereditary
15 Nonpolyposis Colorectal Cancer Syndrome (HNPCC), also known as
Lynch syndrome II, has been ascertained for the majority of kindred's
affected with the disease (14). The molecular basis of HNPCC involves
genetic instability resulting from defective mismatch repair (MMR).
Several genes have been identified in humans that encode for proteins and
20 appear to participate in the MMR process, including the *mutS* homologs
GTBP, *hMSH2*, and *hMSH3* and the *mutL* homologs *hMLH1*, *hMLH3*,
hPMS1, and *hPMS2* (4,9,11,17,19,22,24,38). Germline mutations in four
of these genes (*hMSH2*, *hMLH1*, *hPMS1*, and *hPMS2*) have been identified
in HNPCC kindred's (13). Though the mutator defect that arises from the
25 MMR deficiency can affect any DNA sequence, microsatellite sequences
are particularly sensitive to MMR abnormalities (14, 25, 27, 29).
Microsatellite instability (MI) is therefore a useful indicator of defective
MMR. In addition to its occurrence in virtually all tumors arising in
HNPCC patients, MI is found in a small fraction of sporadic tumors with
30 distinctive molecular and phenotypic properties (13).

HNPCC is inherited in an autosomal dominant fashion, so that the
normal cells of affected family members contain one mutant allele of the

relevant MMR gene (inherited from an affected parent) and one wild-type allele (inherited from the unaffected parent). During the early stages of tumor development, however, the wild-type allele is inactivated through a somatic mutation, leaving the cell with no functional MMR gene and
5 resulting in a profound defect in MMR activity. Because a somatic mutation in addition to a germ-line mutation is required to generate defective MMR in the tumor cells, this mechanism is generally referred to as one involving two hits, analogous to the biallelic inactivation of tumor suppressor genes that initiate other hereditary cancers. In line with this
10 two-hit mechanism, the non-neoplastic cells of HNPCC patients generally retain near normal levels of MMR activity due to the presence of the wild-type allele (11, 13, 24). In addition, similar findings are observed in other diploid organisms (2, 5, 8).

The ability to alter signal transduction pathways by manipulation of
15 a gene product's function, either by over-expression of the wild type protein or a fragment thereof, or by introduction of mutations into specific protein domains of the protein, the so-called dominant-negative inhibitory mutant, were described over a decade ago in the yeast system
Saccharomyces cerevisiae by Herskowitz (Nature 329:219-222, 1987). It
20 has been demonstrated that over-expression of wild type gene products can result in a similar, dominant-negative inhibitory phenotype due most likely to the "saturating-out" of a factor, such as a protein, that is present at low levels and necessary for activity; removal of the protein by binding to a high level of its cognate partner results in the same net effect, leading to
25 inactivation of the protein and the associated signal transduction pathway.

Recently, work done by Nicolaides et.al. (32) has demonstrated the utility of introducing dominant negative inhibitory mismatch repair mutants into mammalian cells to confer global DNA hypermutability. There is a need in the art for additional techniques for generating mutations in bacteria which can be used to make strains for production, biocatalysis, bioremediation, and drug discovery.

SUMMARY OF THE INVENTION

It is an object of the present invention to provide a method for rendering bacterial cells hypermutable.

It is another object of the present invention to provide genetically altered bacteria.

It is yet another object of the present invention to provide a method to produce bacteria that are hypermutable.

It is an object of the invention to provide a method to inactivate the process that results in hypermutable cells following strain selection.

It is a further object of the invention to provide a method of mutating a gene of interest in a bacterium.

These and other embodiments of the invention are provided by one or more of the embodiments described below. In one embodiment, a method is provided for making a hypermutable bacteria. A polynucleotide comprising a dominant negative allele of a mismatch repair gene is introduced into a bacterium, whereby the cell becomes hypermutable. Preferably the allele is under the control of an inducible transcription regulatory sequence.

According to another aspect of the invention a homogeneous composition of cultured, hypermutable, bacteria is provided. The bacteria comprise a dominant negative allele of a mismatch repair gene. Preferably the allele is under the control of an inducible transcription regulatory sequence.

Another embodiment of the invention provides a method for generating a mutation in a gene of interest. A bacterial culture comprising the gene of interest and a dominant negative allele of a mismatch repair gene is grown. The cell is hypermutable. It is tested to determine whether
5 the gene of interest harbors a mutation. Preferably the allele is under the control of an inducible transcription regulatory sequence.

According to still another aspect of the invention a method for generating a mutation in a gene of interest is provided. A bacterium comprising the gene of interest and a dominant negative allele of a
10 mismatch repair gene is grown to form a population of mutated bacteria. The population of mutated bacteria is cultivated under trait selection conditions. At least one of the cultivated bacteria is tested to determine that the gene of interest harbors a mutation. Preferably the allele is under the control of an inducible transcription regulatory sequence.

15 Still another aspect of the invention is a method for enhancing the mutation rate of a bacterium. A bacterium comprising a dominant negative allele of an MMR gene is exposed to a mutagen whereby the mutation rate of the bacterium is enhanced in excess of the rate in the absence of mutagen and in excess of the rate in the absence of the dominant negative allele.
20 Preferably the allele is under the control of an inducible transcription regulatory sequence.

Yet another aspect of the invention is a method for generating an MMR-proficient bacterium with a new output trait. A mismatch repair deficient bacterium comprising a gene of interest and a
25 dominant negative allele of a mismatch repair gene is grown to form a population of mutated bacteria. The population of mutated bacteria is cultivated under trait selection conditions. At least one of the cultivated bacteria is tested to determine that the gene of interest harbors a mutation. Mismatch repair activity is restored to the at least one of the cultivated

bacteria. Preferably the allele is under the control of an inducible transcription regulatory sequence.

- These and other embodiments of the invention provide the art with methods that can generate enhanced mutability in bacteria as well as
- 5 providing prokaryotic organisms harboring potentially useful mutations to generate novel output traits for commercial applications. The ability to create hypermutable organisms using dominant negative alleles has great commercial value for the generation of innovative bacterial strains that display new output features useful for a variety of applications, including
- 10 but not limited to the manufacturing industry for the generation of new biochemicals useful for detoxifying noxious chemicals from by-products of manufacturing processes or those used as catalysts, as well as helping in remediation of toxins present in the environment, including but not limited to polychlorobenzenes (PCBs), heavy metals and other environmental
- 15 hazards for which there is a need to remove them from the environment. In addition to obtaining organisms that are useful for removal of toxins from the environment, novel microbes can be selected for enhanced activity to either produce increased quantity or quality of a protein or non-protein therapeutic molecule by means of biotransformation (3).
- 20 Biotransformation is the enzymatic conversion, by a microbe or an extract derived from the microbe, of one chemical intermediate to the next product. There are many examples of biotransformation in use for the commercial manufacturing of important biological and chemical products, including Penicillin G, Erythromycin, and Clavulanic Acid as well as organisms that
- 25 are efficient at conversion of "raw" materials to advanced intermediates and/or final products (Berry, A. Trends Biotechnol. 14(7):250-256). The ability to control DNA hypermutability in host bacterial strains using a dominant negative MMR (as described above) allows for the generation of variant subtypes that can be selected for new phenotypes of commercial
- 30 interest, including but not limited to organisms that are toxin-resistant, have

the capacity to degrade a toxin *in situ* or the ability to convert a molecule from an intermediate to either an advanced intermediate or a final product. Other applications using dominant negative MMR genes to produce genetic alteration of bacterial hosts for new output traits include but are not limited to recombinant production strains that produce higher quantities of a polypeptide as well as the use of altered endogenous genes that can transform chemical or catalyze manufacturing downstream processes.

This application teaches of the use of a regulatable dominant negative MMR phenotype to produce a prokaryotic strain with a commercially beneficial output trait. Using this process, microbes expressing a dominant negative MMR can be directly selected for the phenotype of interest. Once a selected bacterium with a specified output trait is isolated, the hypermutable activity of the dominant negative MMR allele can be turned-off by several methods well known to those skilled in the art. For example, if the dominant-negative allele is expressed by an inducible promoter system, including but not limited to promoters such as: TAC-LACI, *trp* (Brosius et.al. *Gene* 27:161-172, 1984), *araBAD* (Guzman et.al., *J. Bact.* 177:4121-4130, 1995) *pLex* (La Vallie et.al., *Bio.Technology* 11:187-193, 1992), *pRSET* (Schoepfer, R. *Gene* 124:83-85, 1993) , *pT7* (Studier *J. Mol. Biol.* 219(1):37-44, 1991) etc., the inducer is removed and the promoter activity is reduced, or a system that excises the MMR gene insert from the host cells harboring the expression vector such as the *Cre-lox* (Hasan, N. et.al. *Gene* 2:51-56, 1994), as well as methods that can homologously knockout of the expression vector. In addition to the recombinant methods outlined above that have the capacity to eliminate the MMR activity from the microbe, it has been demonstrated that many chemicals have the ability to "cure" microbial cells of plasmids. For example, chemical treatment of cells with drugs including bleomycin (Attfield et al. *Antimicrob. Agents Chemother.* 27:985-988, 1985) or

novobiocin, coumermycin, and quinolones (Fu et al. *Chemotherapy* 34:415-418, 1988) have been shown to result in microbial cells that lack endogenous plasmid as evidenced by Southern analysis of cured cells as well as sensitivity to the appropriate antibiotic (1, 41-43). Whether by use of recombinant means or treatment of cells with chemicals, removal of the MMR-expression plasmid results in the re-establishment of a genetically stable microbial cell-line. Therefore, the restoration of MMR allows host bacteria to function normally to repair DNA. The newly generated mutant bacterial strain that exhibits a novel, selected output trait is now suitable for a wide range of commercial processes or for gene/protein discovery to identify new biomolecules that are involved in generating a particular output trait.

While it has been documented that MMR deficiency can lead to as much as a 1000-fold increase in the endogenous DNA mutation rate of a host, there is no assurance that MMR deficiency alone will be sufficient to alter every gene within the DNA of the host bacterium to create altered biochemicals with new activity(s). Therefore, the use of chemical agents and their respective analogues such as ethidium bromide, EMS, MNNG, MNU, Tamoxifen, 8-Hydroxyguanine, as well as others listed but not limited to in publications by: Khromov-Borisov, N.N., et.al. (*Mutat. Res.* 430:55-74, 1999); Ohe, T., et.al. (*Mutat. Res.* 429:189-199, 1999); Hour, T.C. et.al. (*Food Chem. Toxicol.* 37:569-579, 1999); Hrelia, P., et.al. (*Chem. Biol. Interact.* 118:99-111, 1999); Garganta, F., et.al. (*Environ. Mol. Mutagen.* 33:75-85, 1999); Ukawa-Ishikawa S., et.al. (*Mutat. Res.* 412:99-107, 1998); www.ehs.utah.edu/ohh/mutagens, etc. can be used to further enhance the spectrum of mutations and increase the likelihood of obtaining alterations in one or more genes that can in turn generate host bacteria with a desired new output trait(s) (10, 39, 40). Prior art teaches that mismatch repair deficiency leads to hosts with an increased resistance to toxicity by chemicals with DNA damaging activity. This feature allows

for the creation of additional genetically diverse hosts when mismatch defective bacteria are exposed to such agents, which would be otherwise impossible due to the toxic effects of such chemical mutagens [Colella, G., et.al. (Br. J. Cancer 80:338-343, 1999); Moreland, N.J., et.al. (Cancer Res. 59:2102-2106, 1999); Humbert, O., et.al. (Carcinogenesis 20:205-214, 1999); Glaab, W.E., et.al. (Mutat. Res. 398:197-207, 1998)]. Moreover, prior art teaches that mismatch repair is responsible for repairing chemical-induced DNA adducts, so therefore blocking this process could theoretically increase the number, types, mutation rate and genomic alterations of a bacterial host [Rasmussen, L.J. et.al. (Carcinogenesis 17:2085-2088, 1996); Sledziewska-Gojska, E., et.al. (Mutat. Res. 383:31-37, 1997); and Janion, C. et.al. (Mutat. Res. 210:15-22, 1989)]. In addition to the chemicals listed above, other types of DNA mutagens include ionizing radiation and UV-irradiation, which are known to cause DNA mutagenesis in bacteria can also be used to potentially enhance this process. These agents which are extremely toxic to host cells and therefore result in a decrease in the actual pool size of altered bacterial cells are more tolerated in MMR defective hosts and in turn allow for an enriched spectrum and degree of genomic mutation (7).

This application teaches new uses of MMR deficient bacterial cells to create commercially viable microbes that express novel output traits. Moreover, this application teaches the use of dominant negative MMR genes to decrease the endogenous MMR activity of the host followed by placing the cells under selection to obtain a desired, sought after output trait for commercial applications such as but not limited to recombinant manufacturing, biotransformation and bioremediation. Furthermore, the application teaches the use of restoring MMR activity to the hypermutable bacterial host following strain selection of the variant of interest as a means to genetically "fix" the new mutations in the host genome. The application also teaches the use of enhanced hypermutability in bacteria by using

- MMR deficiency and chemical or radiation mutagenesis to create variant subtypes of bacteria useful for commercial and other applications. The application describes uses of hypermutable bacteria for producing strains that can be used to generate new output traits for chemical manufacturing, pharmaceutical and other commercially applicable processes.

BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1.** Western blot of steady-state PMS134 levels in IPTG-treated samples in DH10B strain. Cells containing the pTACPMS134 (lane 2) showed a robust steady state level of protein after induction in contrast to cells expressing empty vector (lane 1). Blots were probed with an anti-human-PMS2 polyclonal antibody.
- Figure 2.** Western blot of PMS134V5 and PMSR3V5 in IPTG-treated (+) and untreated (-) samples in BL21 strain. Blots were probed with an anti-V5 antibody, which is directed to the C-terminal tag of each protein.
- Figure 3.** Number of Kanamycin resistant PMS134 and vector control DH10B clones. IPTG-induced strains were grown and plated onto KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.
- Figure 4.** Number of Kanamycin Resistant PMS134, PMSR3 and vector control BL21 clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.
- Figure 5. (A)** Western blot of steady-state ATPMS134flag in IPTG-treated samples in DH10B. Lysates from untransfected cells (lane 1) and a

bacterial clone expressing the Arabidopsis thaliana PMS134 truncated protein with a FLAG epitope fused to the C-terminus (ATPMS134flag) (lane 2) were electrophoresed on SDS-PAGE gels. Blots were probed with an anti-FLAG monoclonal antibody directed to the FLAG epitope. (B)

- 5 Number of Kanamycin Resistant ATPMS134flag and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.
- 10 **Figure 6.** Generation of high recombinant producer BGAL-MOR lines in PMS134 expressing DH5alpha host strains.

DETAILED DESCRIPTION OF THE INVENTION

- 15 The inventors present a method for developing hypermutable bacteria by altering the activity of endogenous mismatch repair activity of hosts. Wild type and some dominant negative alleles of mismatch repair genes, when introduced and expressed in bacteria, increase the rate of spontaneous mutations by reducing the effectiveness of the endogenous
- 20 MMR-mediated DNA repair activity, thereby rendering the bacteria highly susceptible to genetic alterations due to hypermutability. Hypermutable bacteria can then be utilized to screen for novel mutations in a gene or a set of genes that produce variant siblings that exhibit a new output trait(s) not found in the wild type cells.

- 25 The process of mismatch repair, also called mismatch proofreading, is an evolutionarily highly conserved process that is carried out by protein complexes described in cells as disparate as prokaryotic cells such as bacteria to more complex mammalian cells (14, 29, 31, 33, 34). A mismatch repair gene is a gene that encodes one of the proteins of such a
- 30 mismatch repair complex. Although not wanting to be bound by any

particular theory of mechanism of action, a mismatch repair complex is believed to detect distortions of the DNA helix resulting from non-complementary pairing of nucleotide bases. The non-complementary base on the newer DNA strand is excised, and the excised base is replaced with the appropriate base that is complementary to the older DNA strand. In this way, cells eliminate many mutations that occur as a result of mistakes in DNA replication, resulting in genetic stability of the sibling cells derived from the parental cell.

Some wild type alleles as well as dominant negative alleles cause a mismatch repair defective phenotype even in the presence of a wild-type allele in the same cell. An example of a dominant negative allele of a mismatch repair gene is the human gene *hPMS2-134*, which carries a truncation mutation at codon 134 (32). The mutation causes the product of this gene to abnormally terminate at the position of the 134th amino acid, resulting in a shortened polypeptide containing the N-terminal 133 amino acids. Such a mutation causes an increase in the rate of mutations, which accumulate in cells after DNA replication. Expression of a dominant negative allele of a mismatch repair gene results in impairment of mismatch repair activity, even in the presence of the wild-type allele. Any mismatch repair allele, which produces such effect, can be used in this invention. In addition, the use of over-expressed wildtype MMR gene alleles from human, mouse, plants, and yeast in bacteria has been shown to cause a dominant negative effect on the bacterial hosts MMR activity (9, 33, 34, 38).

Dominant negative alleles of a mismatch repair gene can be obtained from the cells of humans, animals, yeast, bacteria, plants or other organisms. Screening cells for defective mismatch repair activity can identify such alleles. Mismatch repair genes may be mutant or wild type. Bacterial host MMR may be mutated or not. The term bacteria used in this application include any organism from the prokaryotic kingdom. These

organisms include genera such as but not limited to *Agrobacterium*, *Anaerobacter*, *Aquabacterium*, *Azorhizobium*, *Bacillus*, *Bradyrhizobium*, *Cryobacterium*, *Escherichia*, *Enterococcus*, *Heliobacterium*, *Klebsiella*, *Lactobacillus*, *Methanococcus*, *Methanothermobacter*, *Micrococcus*,
 5 *Mycobacterium*, *Oceanomonas*, *Pseudomonas*, *Rhizobium*, *Staphylococcus*, *Streptococcus*, *Streptomyces*, *Thermusaquaticus*, *Thermaerobacter*, *Thermobacillus*, etc. Other procaryotes that can be used for this application are listed at (www.bacterio.cict.fr/validgenericnames).

- Bacteria exposed to chemical mutagens or radiation exposure can be
 10 screened for defective mismatch repair. Genomic DNA, cDNA, or mRNA from any cell encoding a mismatch repair protein can be analyzed for variations from the wild type sequence. Dominant negative alleles of a mismatch repair gene can also be created artificially, for example, by producing variants of the *hPMS2-134* allele or other mismatch repair genes
 15 (32). Various techniques of site-directed mutagenesis can be used. The suitability of such alleles, whether natural or artificial, for use in generating hypermutable bacteria can be evaluated by testing the mismatch repair activity (using methods described in ref 32) caused by the allele in the presence of one or more wild-type alleles, to determine if it is a dominant
 20 negative allele.

- A bacterium that over-expresses a wild type mismatch repair allele or a dominant negative allele of a mismatch repair gene will become hypermutable. This means that the spontaneous mutation rate of such bacteria is elevated compared to bacteria without such alleles. The degree
 25 of elevation of the spontaneous mutation rate can be at least 2-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold, 500-fold, or 1000-fold that of the normal bacteria as measured as a function of bacterial doubling/minute.

- According to one aspect of the invention, a polynucleotide encoding either a wild type or a dominant negative form of a mismatch repair protein
 30 is introduced into bacteria. The gene can be any dominant negative allele

encoding a protein which is part of a mismatch repair complex, for example, *mutS*, *mutL*, *mutH*, or *mutY* homologs of the bacterial, yeast, plant or mammalian genes (14, 28). The dominant negative allele can be naturally occurring or made in the laboratory. The polynucleotide can be in the form of genomic DNA, cDNA, RNA, or a chemically synthesized polynucleotide or polypeptide. The molecule can be introduced into the cell by transfection, transformation, conjugation, fusion, or other methods well described in the literature.

Any process can be used whereby a polynucleotide or polypeptide is introduced into a cell. The process of gene transfer can be carried out in a bacterial culture using a suspension culture. The bacteria can be any type classified under the prokaryotes.

In general, gene transfer will be carried out using a suspension of cells but other methods can also be employed as long as a sufficient fraction of the treated cells incorporate the polynucleotide or polypeptide so as to allow recipient cells to be grown and utilized. The protein product of the polynucleotide may be transiently or stably expressed in the cell. Techniques for gene transfer are well known to those skilled in the art. Available techniques to introduce a polynucleotide or polypeptide into a prokaryote include but are not limited to electroporation, transduction, cell fusion, the use of chemically competent cells (e.g. calcium chloride), and packaging of the polynucleotide together with lipid for fusion with the cells of interest. Once a cell has been transformed with the dominant negative mismatch repair gene or protein, the cell can be propagated and manipulated in either liquid culture or on a solid agar matrix, such as a petri dish. If the transfected cell is stable, the gene will be retained and expressed at a consistent level when the promoter is constitutively active, or when in the presence of appropriate inducer molecules when the promoter is inducible, for many cell generations, and a stable, hypermutable bacterial strain results.

An isolated bacterial cell is a clone obtained from a pool of a bacterial culture by chemically selecting out non-recipient strains using, for example, antibiotic selection of an expression vector. If the bacterial cell is derived from a single cell, it is defined as a clone.

5 A polynucleotide encoding a dominant negative form of a mismatch repair protein can be introduced into the genome of a bacterium or propagated on an extra-chromosomal plasmid. Selection of clones harboring the mismatch repair gene expression vector can be accomplished by addition of any of several different antibiotics, including but not limited
10 to ampicillin, kanamycin, chloramphenicol, zeocin, and tetracycline. The microbe can be any species for which suitable techniques are available to produce transgenic microorganisms, such as but not limited to genera including *Bacillus*, *Pseudomonas*, *Staphylococcus*, *Escherichia* and others.

Any method for making transgenic bacteria known in the art can be
15 used. According to one process of producing a transgenic microorganism, the polynucleotide is transfected into the microbe by one of the methods well known to those in the art. Next, the microbial culture is grown under conditions that select for cells in which the polynucleotide encoding the mismatch repair gene is either incorporated into the host genome as a stable
20 entity or propagated on a self-replicating extra-chromosomal plasmid, and the protein encoded by the polynucleotide fragment transcribed and subsequently translated into a functional protein within the cell. Once transgenic microbe is engineered to harbor the expression construct, it is then propagated to generate and sustain a culture of transgenic microbes
25 indefinitely.

Once a stable, transgenic microorganism has been engineered to express a functional mismatch repair (MMR) protein, the microbe can be exploited to create novel mutations in one or more target gene(s) of interest harbored within the same microorganism. A gene of interest can be any
30 gene naturally possessed by the bacterium or one introduced into the

bacterial host by standard recombinant DNA techniques. The target gene(s) may be known prior to the selection or unknown. One advantage of employing such transgenic microbes to induce mutations in resident or extra-chromosomal genes within the microbe is that it is unnecessary to expose the microorganism to mutagenic insult, whether it be chemical or radiation in nature, to produce a series of random gene alterations in the target gene(s). This is due to the highly efficient nature and the spectrum of naturally occurring mutations that result as a consequence of the altered mismatch repair process. However, it is possible to increase the spectrum and frequency of mutations by the concomitant use of either chemicals and/or radiation together with MMR defective cells. These include DNA mutagens, DNA alkylating agents, DNA intercalating agents, DNA oxidizing agents, ionizing radiation, and ultraviolet radiation. The net effect of the combination treatment is the increase in altered gene pool in the genetically altered microbe that result in an increased alteration of an allele(s) that are useful for producing new output traits. Another benefit of using MMR-defective microbes that are taught in this application is that one can perform a genetic screen for the direct selection of variant sub-clones that exhibit new output traits with commercially important applications. This allows one to bypass tedious and time consuming gene identification, isolation and characterization.

Mutations can be detected by analyzing the recombinant microbe for alterations in the genotype and/or phenotype post-activation of the decreased mismatch repair activity of the transgenic microorganism. Novel genes that produce altered phenotypes in MMR-defective microbial cells can be discerned by any variety of molecular techniques well known to those in the art. For example, the microbial genome can be isolated and a library of restriction fragments cloned into a plasmid vector. The library can be introduced into a "normal" cell and the cells exhibiting the novel phenotype screened. A plasmid is isolated from those normal cells that

- exhibit the novel phenotype and the gene(s) characterized by DNA sequence analysis. Alternatively, differential messenger RNA screen can be employed utilizing driver and tester RNA (derived from wild type and novel mutant respectively) followed by cloning the differential transcripts and characterizing them by standard molecular biology methods well known to those skilled in the art. Furthermore, if the mutant sought is on encoded by an extrachromosomal plasmid, then following co-expression of the dominant negative MMR gene and the gene of interest to be altered and phenotypic selection, the plasmid is isolated from mutant clones and analyzed by DNA sequence analysis by methods well known to those in the art. Phenotypic screening for output traits in MMR-defective mutants can be by biochemical activity and/or a physical phenotype of the altered gene product. A mutant phenotype can also be detected by identifying alterations in electrophoretic mobility, DNA binding in the case of transcription factors, spectroscopic properties such as IR, CD, X-ray crystallography or high field NMR analysis, or other physical or structural characteristics of a protein encoded by a mutant gene. It is also possible to screen for altered novel function of a protein *in situ*, in isolated form, or in model systems. One can screen for alteration of any property of the microorganism associated with the function of the gene of interest, whether the gene is known prior to the selection or unknown. The aforementioned screening and selection discussion is meant to illustrate the potential means of obtaining novel mutants with commercially valuable output traits.

- Plasmid expression vectors that harbor the mismatch repair (MMR) gene inserts can be used in combination with a number of commercially available regulatory sequences to control both the temporal and quantitative biochemical expression level of the dominant negative MMR protein. The regulatory sequences can be comprised of a promoter, enhancer or promoter/enhancer combination and can be inserted either upstream or downstream of the MMR gene to control the expression level. The

regulatory promoter sequence can be any of those well known to those in the art, including but not limited to the lacI, tetracycline, tryptophan-inducible, phosphate inducible, T7-polymerase-inducible (30), and steroid inducible constructs as well as sequences which can result in the excision of the dominant negative mismatch repair gene such as those of the Cre-Lox system. These types of regulatory systems are familiar to those skilled in the art.

Once a microorganism with a novel, desired output trait of interest is created, the activity of the aberrant MMR activity can be attenuated or eliminated by any of a variety of methods, including removal of the inducer from the culture medium that is responsible for promoter activation, gene disruption of the aberrant MMR gene constructs, electroporation and/or chemical curing of the expression plasmids (Brosius, Biotechnology 10:205-225, 1988; Wang et al., J. of Fujian Agricultural University 28:43-46, 1999; Fu et. al., Chem Abstracts 34:415-418, 1988). The resulting microbe is now useful as a stable strain that can be applied to various commercial applications, depending upon the selection process placed upon it.

In cases where genetically deficient mismatch repair bacteria [strains such as but not limited to: M1 (mutS) and in EC2416 (mutS delta umuDC), and mutL or mutY strains] are used to derive new output traits, transgenic constructs can be used that express wild-type mismatch repair genes sufficient to complement the genetic defect and therefore restore mismatch repair activity of the host after trait selection [Grzesiuk, E. et.al. (Mutagenesis 13:127-132, 1998); Bridges, B.A., et.al. (EMBO J. 16:3349-3356, 1997); LeClerc, J.E., Science 15:1208-1211, 1996; Jaworski, A. et.al. (Proc. Natl. Acad. Sci USA 92:11019-11023, 1995)]. The resulting microbe is genetically stable and can be applied to various commercial practices.

The use of over expressing foreign mismatch repair genes from human and yeast such as PMS1, MSH2, MLH1, MLH3, etc. have been previously demonstrated to produce a dominant negative mutator phenotype in bacterial hosts (35, 36, 37). In addition, the use of bacterial strains expressing prokaryotic dominant negative MMR genes as well as hosts that have genomic defects in endogenous MMR proteins have also been previously shown to result in a dominant negative mutator phenotype (29,32). However, the findings disclosed here teach the use of MMR genes, including the human PMSR2 and PMSR3 gene (ref 19), the related PMS134 truncated MMR gene (ref 32), the plant mismatch repair genes (SARAH include Plant patent application) and those genes that are homologous to the 134 N-terminal amino acids of the PMS2 gene which include the MutL family of MMR proteins and including the PMSR and PMS2L homologs described by Hori et.al. (accession number NM_005394 and NM_005395) and Nicolaides (reference 19) to create hypermutable microbes. In addition, this application teaches the use of DNA mutagens in combination with MMR defective microbial hosts to enhance the hypermutable production of genetic alterations. This accentuates MMR activity for generation of microorganisms with commercially relevant output traits such as but not limited to recombinant protein production strains, biotransformation, and bioremediation.

The above disclosure generally describes the present invention. A more complete understanding can be obtained by reference to the following specific examples that will be provided herein for purposes of illustration only, and are not intended to limit the scope of the invention

EXAMPLES

Example 1: Generation of inducible MMR dominant negative allele vectors

Bacterial expression constructs were prepared to determine if the human PMS2 related gene (hPMSR3) (19) and the human PMS134 gene (32) are capable of inactivating the bacterial MMR activity and thereby increase the overall frequency of genomic hypermutation, a consequence of which is the generation of variant sib cells with novel output traits following host selection. Moreover, the use of regulatable expression vectors will allow for suppression of dominant negative MMR alleles and restoration of the MMR pathway and genetic stability in hosts cells (43). For these studies, a plasmid encoding the hPMS134 cDNA was altered by polymerase chain reaction (PCR). The 5' oligonucleotide has the following structure: 5'-ACG CAT ATG GAG CGA GCT GAG AGC TCG AGT-3' that includes the NdeI restriction site CAT ATG. The 3'-oligonucleotide has the following structure: 5'-GAA TTC TTA TCA CGT AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC AGT TCC AAC CTT CGC CGA TGC-3' that includes an EcoRI site GAA TTC and the 14 amino acid epitope for the V5 antibody. The oligonucleotides were used for PCR under standard conditions that included 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C). The PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (InVitrogen) by standard cloning methods (Sambrook et al., Molecular Cloning: A Laboratory Manual, Third Edition, 2001), creating the plasmid pTA2.1-hPMS134. pTA2.1-hPMS134 was digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment filled in with Klenow fragment and dNTPs. Next, the fragment was gel purified, then digested with NdeI and inserted in pT7-Ea that had been digested with NdeI and BamHI (filled

- with Klenow) and phosphatase treated. The new plasmid was designated pT7-Ea-hPMS134. The following strategy, similar to that described above to clone human PMS134, was used to construct an expression vector for the human related gene PMSR3. First, the hPMSR3 fragment was amplified
- 5 by PCR to introduce two restriction sites, an NdeI restriction site at the 5'-end and an EcoRI site at the 3'-end of the fragment. The 5'-oligonucleotide that was used for PCR has the following structure: 5'-ACG CAT ATG TGT CCT TGG CGG CCT AGA-3' that includes the NdeI restriction site CAT ATG. The 3'-oligonucleotide used for PCR has the
- 10 following structure: 5'-GAA TTC TTA TTA CGT AGA ATC GAG ACC GAG GAG AGG GTT AGG GAT AGG CTT ACC CAT GTG TGA TGT TTC AGA GCT-3' that includes an EcoRI site GAA TTC and the V5 epitope to allow for antibody detection. The plasmid that contained human PMSR3 in pBluescript SK (19) was used as the PCR target with the
- 15 hPMS2-specific oligonucleotides above. Following 25 cycles of PCR (95°C for 1 minute, 55°C for 1 minute, 72°C for 1.5 minutes for 25 cycles followed by 3 minutes at 72°C). The PCR fragment was purified by gel electrophoresis and cloned into pTA2.1 (Invitrogen) by standard cloning methods (Sambrook et al., Molecular Cloning: A Laboratory Manual, Third
- 20 Edition, 2001), creating the plasmid pTA2.1-hR3. pTA2.1-hR3 was next digested with the restriction enzyme EcoRI to release the insert (there are two EcoRI restriction sites in the multiple cloning site of pTA2.1 that flank the insert) and the fragment filled in with Klenow fragment and dNTPs. Then, the fragment was gel purified, then digested with NdeI and inserted
- 25 in pT7-Ea that had been digested with NdeI and BamHI (filled with Klenow) and phosphatase treated. The new plasmid was designated pT7-Ea-hR3.

- BL21 cells harbor an additional expression vector for the lysozyme protein, which has been demonstrated to bind to the T7 polymerase in situ;
- 30 this results in a bacterial strain that has very low levels of T7 polymerase

expression. However, upon addition of the inducer IPTG, the cells express high-levels of T7 polymerase due to the IPTG-inducible element that drives expression of the polymerase that is resident within the genome of the BL21 cells (30). The BL21 cells are chloramphenicol resistant due to the plasmid that expresses lysozyme within the cell. To introduce the pT7-hPMS134 or the pT7-hPMSR3 genes into BL21 cells, the cells were made competent by incubating the cells in ice cold 50mM CaCl₂ for 20 minutes, followed by concentrating the cells and adding super-coiled plasmid DNA as describe (Maniatis, T.et.al. Cold Spring Harbor Laboratory Press, Third Edition, 2001). Ampicillin resistant BL21 were selected on LB-agar plates [5% yeast extract, 10% bactotryptone, 5% NaCl, 1.5% bactoagar, pH 7.0 (Difco)] plates containing 25 µg/ml chloramphenicol and 100µg/ml ampicillin. The next day, bacterial colonies were picked and analyzed for vectors containing an intact pTACPMS134 or pTAC empty vector by restriction endonuclease digestion and sequence analysis.

In addition to constructing a V5-epitope tagged PMS134 construct we also constructed and tested a non-epitope tagged version. This was prepared to demonstrate that the simple fact of epitope tagging the construct did not result in alteration of the dominant-negative phenotype that PMS134 has on mismatch repair activity. For these studies, a BamHI restriction fragment containing the hPMS134 cDNA was filled-in with Klenow fragment and then sub-cloned into a Klenow-filled blunt-ended NdeI-XhoI site of the pTACLAC expression vector, which contains the isopropylthio-β-galactosidase (IPTG)-inducible bacterial TAC promoter and ampicillin resistance gene as selectable marker. The NdeI-XhoI cloning site is flanked by the TACLAC promoter that contains the LacI repressor site followed by a Shine Dalgarno ribosome-binding site at the 5' flanking region and the T1T2 ribosomal RNA terminator in the 3' flanking region. The TACLAC vector also contains the LacI gene, which is constitutively expressed by the TAC promoter.

DH10B bacterial cells containing the pBCSK vector (Stratagene), which constitutively expresses the β -galactosidase gene and contains the chloramphenicol resistance marker for selection, were made competent via the CaCl_2 method (Maniatis, T. et al. Cold Spring Harbor Laboratory Press, 1982). This vector turns bacterial cells blue when grown in the presence of IPTG and X-gal that aids in the detection of bacterial colonies. Competent cells were transfected with the pTAC empty vector or the pTACPMS134 vector following the heat-shock protocol. Transfected cultures were plated onto LB-agar [5% yeast extract, 10% bactotryptone, 5% NaCl, 1.5% bactoagar, pH 7.0 (Difco)] plates containing 25 $\mu\text{g/ml}$ chloramphenicol and 100 $\mu\text{g/ml}$ ampicillin. The next day, bacterial colonies were picked and analyzed for vectors containing an intact pTACPMS134 or pTAC empty vector by restriction endonuclease digestion and sequence analysis. Ten clones of each bacteria containing correct empty or PMS134 inserts were then grown to confluence overnight in LB media (5% yeast extract, 10% bactotryptone, 5% NaCl, pH 7.0) containing 10 $\mu\text{g/ml}$ chloramphenicol and 50 $\mu\text{g/ml}$ ampicillin. The next day TAC empty or pTACPMS134 cultures were diluted 1:4 in LB medium plus 50 μM IPTG (Gold Biotechnology) and cultures were grown for 12 and 24 hours at 37°C. After incubation, 50 μl aliquots were taken from each culture and added to 150 μl of 2X SDS buffer and cultures were analyzed for PMS134 protein expression by western blot.

Western blots were carried out as follows. 50 μl of each PMS134 or empty vector culture was directly lysed in 2X lysis buffer (60 mM Tris, pH 6.8, 2% SDS, 10% glycerol, 0.1 M 2-mercaptoethanol, 0.001% bromophenol blue) and samples were boiled for 5 minutes. Lysate proteins were separated by electrophoresis on 4-20% Tris glycine gels (Novex). Gels were electroblotted onto Immobilon-P (Millipore) in 48 mM Tris base, 40 mM glycine, 0.0375% SDS, 20% methanol and blocked overnight

at 4°C in Tris-buffered saline plus 0.05% Tween-20 and 5% condensed milk. Filters were probed with a rabbit polyclonal antibody generated against the N-terminus of the human PMS2 polypeptide (Santa Cruz), which is able to recognize the PMS134 polypeptide (31), followed by a secondary goat anti-rabbit horseradish peroxidase-conjugated antibody. After incubation with the secondary antibody, blots are developed using chemiluminescence (Pierce) and exposed to film to measure PMS134 expression.

As shown in Figure 1, a robust expression of PMS134 could be detected in bacterial cells containing pTACPM134 (lane 2) in contrast to cells expressing empty vector (lane 1), which had no signal.

For induction of PMS134 and PMSR3 in BL21 cells, the pT7-Ea-hPMS134 or the pT7-Ea-hPMSR3 cells were induced with 50µM IPTG for 12 and 24 hours. Cell lysates were prepared and analyzed by western blot listed above using either the N-terminal PMS2 antibody to detect the PMS134 containing cells or the antiV5-horseradish peroxidase conjugated monoclonal antibody (InVitrogen) to detect the PMS134V5 and PMSR3V5 polypeptides. Figure 2 shows the expression of PMS134V5 and PMSR3V5 before (-) lanes and after IPTG (+) lanes induction.

20

Example 2: Generation of hypermutable bacteria with inducible dominant negative alleles of mismatch repair genes

Bacterial clones expressing the *PMS134* or the empty vector were grown in liquid culture for 24 hr at 37°C in the presence of 10 µg/ml chloramphenicol and 50 µg/ml ampicillin plus 50µM IPTG. The next day, cultures were diluted 1:10 in medium containing 50µM IPTG plus ampicillin/chloramphenicol (AC) or ampicillin/chloramphenicol plus 25 µg/ml kanamycin (ACK) and cultures were grown for 18 hr at 37°C. The following day, a 0.1 µl aliquot (2 µl diluted in 1000 µl of LB medium and

30

used 50 µl for plating) of cells grown in AC medium were plated on LB-agar plates containing 40 µg/ml of 5-bromo-4-chloro-3-indolyl-B-D-galactoside (X-gal) plus 100µg/ml ampicillin (AMP), while a 1 µl aliquot (1 µl diluted in 100 µl of LB medium and used 100 µl for plating) of cells
5 grown in ACK medium were plated on LB-agar plates containing X-gal and 50µg/ml kanamycin (KAN). Plates were incubated for 18 hours at 37°C. The results from these studies show that cells expressing the *PMS134* were able to increase hypermutation in the genome of the DH10B bacterial strain which resulted in the production of siblings that exhibit new
10 biological traits such as KAN resistance (Figure 3).

Kanamycin-resistant assays using BL21 cells expressing the V5-tagged or untagged PMS134 or PMSR3 polypeptides were carried out as described above. BL21 bacterial cells that harbor the empty vector, pT7-PMS134 or pT7-PMSR3 were grown overnight in
15 LB supplemented with 100ug/ml ampicillin. The overnight cultures were diluted 1:100 into fresh ampicillin containing medium and grown for 2.5 hours at 37°C with continuous shaking. When the cells reached an optical density (OD) of 0.6, measured at 600nm, IPTG was added to each culture to a final concentration of 0.5mM. Cells
20 were incubated for 24, and 48 hours; at those time points cells were removed for SDS-PAGE analysis and plating (see above). BL21/pT7 (empty vector), BL21/pT7-PMS134, and BL21/pT7-R3 cells were plated onto LB plates, LB plates that contained 100ug/ml ampicillin, and plates that contain 50ug/ml Kanamycin. The
25 equivalent of 1×10^7 cells/plate were spread onto the plates. BL21 cells that harbor the empty vector are capable of growth on LB plates as well as LB plates that contain 100ug/ml ampicillin; that is as expected since the pT7 expression vector renders the cells ampicillin resistant. The vector only control is not capable of growth on
30 Kanamycin. After 24hr IPTG-induction PMS134 or PMSR3 cells

- had a significant number of KAN resistant cells while none were observed in BL21 parental cells grown under similar conditions (Figure 4). Moreover, BL21 cells containing the PMS134 or PMSR3 genes under non-IPTG-induced conditions failed to produce any
- 5 KAN resistant clones demonstrating the need for expression of the PMS polypeptides for hypermutability. A summary outlining the data and number of Kanamycin resistant bacterial clones is provided in TABLE 1.

10 **TABLE 1. Generation of Kanamycin resistant clones via MMR deficiency**

STRAIN	# CELLS SEEDED	AMP ^R colonies	KAN ^R colonies	FREQUENCY
DH10B VEC	50,000	62,000	0	0
DH10B PMS134	50,000	43,146	23	5.3×10^{-4}
BL21 VEC	500,000	520,800	0	0
BL21 T7-Ea-PMS134V5	500,000	450,000	2,245	4.9×10^{-3}
BL21 T7-Ea-PMSR3V5	500,000	500,000	1,535	3.1×10^{-3}

- These data demonstrate and enable the proof-of-concept that the use of the dominant negative MMR genes is a viable approach to creating hypermutable bacteria that can lead to the generation of phenotypically
- 15 diverse offspring when put under selective conditions.

Using the same protocol as listed above and the same cloning strategy, a truncated PMS2 homolog from the *Arabidopsis thaliana* plant (reference the PLANT patent), which was cloned by degenerate PCR from an *Arabidopsis thaliana* cDNA library

(Stratagene), was found to give a similar enhancement of genetic hypermutability in DH5alpha bacteria Figure 5. For detection purposes, we fused a FLAG epitope to the C-terminus of the PMS134 polypeptide using PCR and an antisense primer directed to the 134 codon region of the *Arabidopsis* PMS2 homolog followed by a FLAG epitope and 2 termination codons. The resultant fusion was termed ATPMS134-flag. The AT PMS134-flag gene was then cloned into the IPTG-inducible TACLAC expression vector and transfected into DH5alpha cells. Western blot of bacteria transfected with an IPTG-inducible expression vector carrying a truncated version (codons 1-134) of the *Arabidopsis thaliana* PMS2 homolog using the anti-FLAG antibody demonstrated the inducibility and steady-state protein levels of the chimeric gene. Figure 5A shows the western blot containing protein from an untransfected cell (lane 1) and a bacterial clone expressing the *Arabidopsis* PMS2-134 truncated protein (lane 2). Following the mutagenesis protocol described above, bacterial cells expressing the ATPMS134 protein were found to have an increase in the number of KAN resistant cells (12 clones) in contrast to cells expressing the empty vector that yielded no KAN resistant clone.

Bacterial cells such as the pT7-PMS134 and pT7-R3 harboring BL21 cells; the TACLACPMS134 DH10B; the TACLACMLH1 DH10B cells; or the TACLAC-ATPMS134flag DH5alpha cells are capable of growth on LB, LB/ampicillin and LB/KAN plates because the cells have acquired mutations within their genome that render the cell drug resistant. Cells that express dominant negative MMR genes have altered the mismatch control pathway of the microbe, presumably altering a gene or a set of genes that control resistance to kanamycin. A new output trait, Kanamycin-resistance, is generated by expression of the dominant negative MMR

gene in these cells. These data demonstrate the ability of dominant negative MMR genes to produce hypermutability across a wide array of bacterial strains to produce new output traits such as Kanamycin resistance.

5

EXAMPLE 3: Dominant negative MMR genes can produce new genetic variants and commercially viable output traits in prokaryotic organisms.

10

The data presented in EXAMPLE 2 show the ability to generate genetic alterations and new phenotypes in bacterial strains expressing dominant negative MMR genes. In this EXAMPLE we teach the utility of this method to create prokaryotic strains with commercially relevant output traits.

15

GENERATION OF HEAT-RESISTANT PRODUCER STRAINS.

One example of commercial utility is the generation of heat-resistant recombinant protein producer strains. In the scalable process of recombinant manufacturing, large-scale fermentation of prokaryotes results in the generation of heat, which leads to suboptimal growth conditions for the producer strain and thus resulting in lower recombinant protein yields. In order to circumvent this problem, we employed the use of DH10B bacteria containing the inducible TACLACPM5134 gene. Briefly, cells were grown in 5 ml LB shake flasks containing ampicillin and IPTG-induced for 0, 24 and 48hrs at 37C. Cultures were harvested and then incubated at 100C for 0, 1 or 10 minutes (times at which 100% of the wild-type strain perishes) and 100 µl aliquots (equivalent to 250,000 cells) were
20
25
30 plated onto LB agar plates containing ampicillin to identify heat

- resistant clones. Table 2 shows a typical experiment whereby cells containing the TACLACPMS134 gene generated a significant number of heat-resistant clones after 48 hours of PMS134 induction and hypermutation via MMR blockade. No or a few clones were observed in the uninduced or 24hr induced conditions respectively suggesting the needs for multiple rounds of genetic mutation to produce genes that are capable of allowing bacteria to survive under harsh conditions. Similar results were observed with other dominant negative mutants such as the PMSR2, PMSR3, and the human MLH1 proteins (not shown).

TABLE 2. Generation of heat-resistant clones via MMR deficiency

Treatment	Heated 0 min	Heated 1 min	Heated 10 min
TACLACVEC 0 hr IPTG	250,000 +/- 7,500	0	0
TACLACPMS134 0 hr IPTG	265,000 +/- 2,000	0	0
TACLACVEC 24 hr IPTG	274,000 +/- 12,000	1 +/- 0	0
TACLACPMS134 24 hr IPTG	240,000 +/- 9,400	5 +/- 2	0
TACLACVEC 48 hr IPTG	256,000 +/- 12,000	0	0
TACLACPMS134 48 hr IPTG	252,000 +/- 14,000	65 +/- 8	3 +/- 1

15 GENERATION OF HIGH RECOMBINANT PROTEIN PRODUCER STRAINS.

- Next, we tested the ability of bacteria expressing dominant negative MMR genes to produce subclones with enhanced recombinant protein production. In these experiments again we employed the DH10B cells containing the TACLACPMS134 inducible vector plus the pTLACZ vector, which constitutively

- expresses the β -galactosidase gene. Analysis of individual clones containing the TACLACPMS134 and pTLACZ vector typically produces 10-20 μ g/ml of LACZ protein via shake flask fermentation after IPTG induction for 24 hours. To test the hypothesis that high recombinant producer strains can be generated by decreased MMR in bacterial strains, we induced the TACLACPMS134-pTLACZ cells for 48 hours with IPTG as described above. We then diluted the culture 1:50 in LB medium, grew the strain for 24 hours, and plated 10 μ ls of culture (diluted in 300 μ ls of LB) onto LB amp-XGAL plates to identify candidate clones that produce robust levels of recombinant LACZ protein. As a control, uninduced cells were treated similarly and plated onto LB amp-XGAL plates. Analysis of the plates revealed a number of bacterial colonies exhibiting a number of clones with an intense BLUE staining in the
- 15 TACLACPMS134/pTLACZ cells induced with IPTG but none were observed in uninduced clones (Figure 6). To confirm that these clones produced an enhanced level of LACZ, we expanded 2 clones with an average BLUE stain (BGAL-C1 and BGAL-C2) and 10 clones with a robust BLUE staining (BGAL-MOR1 to BGAL-MOR10). We grew all clones in LB AMP for 24 hours without IPTG and replated the clones. Six out of ten BGAL-MOR clones resulted in a more robust β -gal stain *in situ* as compared to control "average" cells (BGALC1 and C2). We next performed a more quantitative assay using a β -gal ELISA assay. Briefly, 2 mls of cell centrifuged at 10,000gs for 10 minutes and resuspended in 0.5 mls of 0.25M Tris, pH 7.5 plus 0.0001% Tween-20. Cells were freeze-thawed 4X's and vortexed for 4 minutes at room temperature. Lysates were cleared of debris by centrifugation and supernatants were collected. Protein extracts were quantified for total protein using the Bradford assay
- 20 (BioRad) as described by the manufacturer. Plate ELISAs were
- 30

- carried out by coating 96 well maxisorb (NUNC) plates with 0.1 ml
of a 1 µg/ml (diluted in PBS pH7.0) bacterial extract solution and a
dose range of recombinant β-GAL (Sigma) from 0.001 to 10 mg/ml.
All samples were plated in triplicates. Plates were coated for 2 hours,
5 washed 2 times with PBS and blocked with 0.2mls of PBS plus 5%
powdered milk for 30 minutes. Next, plates were washed once with
PBS and incubated with an anti-β-galactosidase monoclonal antibody
that recognizes both native and denatured forms (Sigma) for 2 hours.
Plates were then washed 3 times with PBS and incubated with 0.1
10 mls of an anti-mouse horseradish peroxidase conjugated antibody for
1 hour at room temperature. Plates were washed 3 times with PBS
and incubated with TMB ELISA substrate (BioRad) for 15 to 30
minutes. Reactions were stopped with 0.1N H₂SO₄ and read on a
BioRAD plate reader at 415nm. The control clones produced
15 roughly 9 and 13 µgs /ml of β-gal while BGAL-MOR clones 2, 3 and
9 produced 106, 82 and 143 µgs /ml of β-gal. To determine if reason
that these clones produced more β-gal was due to mutations in the
plasmid promoter elements, we isolated the pTLACZ plasmid and
retransfected it into DH10B cells as described above. *In situ* analysis
20 found the resultant clones to produce similar amount of β-gal as that
of the control. These data suggest that the BGAL-MOR 2, 3, and 9
hosts had alterations, which results in elevated expression and/or
stability of recombinant proteins.

- To determine if the enhanced *in situ* β-gal expression that was
25 observed in BGAL-MOR clones 1, 5, and 6, which did not appear to
have enhanced β-gal protein levels (had less than 15 µg/ml as
determined by ELISA) was authentic, we performed a more
quantitative assay on these lines plus the BGAL-MOR 9, the
BGALC1 and C2 lines as control. Cells containing an empty vector

- (without a LACZ gene) were used as negative control. To measure β -gal activity, we employed a colorimetric β -gal substrate assay using CPRG (Roche) as described (31). Briefly, 5 μ g of protein extract isolated for ELISA analysis (described above) were analyzed using a plate assay. Protein was added to buffer containing 45 mM 2-mercaptoethanol, 1mM $MgCl_2$, 0.1 M $NaPO_4$ and 0.6 mg/ml Chlorophenol red- β -D-galactopyranoside (CPRG, Roche). Reactions were incubated for 1 hour, terminated by the addition of 0.5 M Na_2CO_3 , and analyzed by spectrophotometry at 576 nm in a BioRad plate reader. Analysis of these extracts confirmed our *in situ* data that these cells did have increased β -gal activity (TABLE 3).

TABLE 3. Generation of bacterial clones with increased β -gal enzymatic activity via MMR deficiency.

Clone	β -gal protein (μ g/ml)	β -gal activity (O.D. 576)
BGAL-C1	9	0.413 +/- .092
BGAL-C2	13	0.393 +/- .105
BGAL-MOR1	14	0.899 +/- .134
BGAL-MOR5	13	0.952 +/- .133
BGAL-MOR6	15	0.923 +/- .100
BGAL-MOR9	143	0.987 +/- .106
Empty vector	-	0.132 +/- .036

Because there was no observable increase in the amount of β -gal protein one likely hypothesis is that the β -gal gene structure was mutated during the hypermutability growth stage and now produces a

more active enzyme. Sequence analysis confirms that this may be the reason for enhanced activity in a subset of clones.

Together, these data demonstrate the ability to produce genetically altered prokaryotic host strains using dominant negative MMR genes to generate commercially valuable output traits such as high recombinant protein producer lines and structurally altered enzymes with enhanced activities.

EXAMPLE 4: Mutations in the host genome generated by defective MMR are genetically stable

As described in EXAMPLE 2 and 3, manipulation of the MMR pathway in microbes results in alterations within the host genome and the ability to select for a novel output traits. It is important that the mutations introduced as a result of defective MMR is genetically stable and passed on to daughter cells once a desired output pathway is established. To determine the genetic stability of mutations introduced into the microbial genome the following experiment was performed. Five independent colonies from pT7-PMS134 and pT7-PMSR3 that are kanamycin resistance were grown overnight from an isolated colony in 5 ml of LB. Next, 1 μ L of the overnight culture from these cultures were inoculated into another 5 mL of LB and grown overnight to saturation. Under these growth conditions the microbial cells have divided over 20 generations. Therefore, if the new output trait generated by alteration of MMR is unstable, the cells should "revert" back from kanamycin resistance to kanamycin sensitivity. Cells were plated onto LB plates and incubated overnight at 37°C. Next, the colonies (about 1,000/plate) were replica plated to LB, LB^{amp¹⁰⁰}, and LB^{kan⁵⁰} plates and incubated at 37°C overnight. Analysis of clones from these studies reveal that a

strict correlation occurs with loss of dominant negative MMR expression and phenotype stability. No loss of KAN resistant clones generated in Example 3 were observed when cells were grown in the absence of IPTG (not expressing PMS134), while 5 revertants out of 5 1200 were observed in clones the were continually grown in IPTG (express PMS134). Extended culturing of cells and replica plating found no reversions of KAN resistance in cultures grown in the absence of IPTG, which produce no PMS134 as determined by western blot (data not shown).

10 These data demonstrate the utility of employing inducible expression systems and dominant negative MMR genes in prokaryotes to generate genetically altered strains for commercial applications such as but not limited to enhanced recombinant manufacturing and biotransformation that can then in turn be restored
15 to a genetically stable host with a "fixed" new genotype that is suitable for commercial processes.

EXAMPLE 5: Enhanced Generation of MMR-Defective Bacteria and Chemical Mutagens for the Generation of New Output

20 Traits

It has been previously documented that MMR deficiency yields to increased mutation frequency and increased resistance to toxic effects of chemical mutagens (CM) and their respective analogues such as but not
25 limited to those as: ethidium bromide, EMS, MNNG, MNU, Tamoxifen, 8-Hydroxyguanine, as well as others listed but not limited to in publications by: Khromov-Borisov, N.N., et.al. (Mutat. Res. 430:55-74, 1999); Ohe, T., et.al. (Mutat. Res. 429:189-199, 1999); Hour, T.C. et.al. (Food Chem. Toxicol. 37:569-579, 1999); Hrelia, P., et.al. (Chem. Biol. Interact. 118:99-
30 111, 1999); Garganta, F., et.al. (Environ. Mol. Mutagen. 33:75-85, 1999);

Ukawa-Ishikawa S., et.al. (Mutat. Res. 412:99-107, 1998);
www.ehs.utah.edu/ohh/mutagens, etc. To demonstrate the ability of CMs
to increase the mutation frequency in MMR defective bacterial cells, we
exposed T7-PMS134 BL21 cells to CMs.

- 5 T7-PMS134 cells and empty vector control cells were grown with
IPTG for 48 hours and then diluted 1: 50 in LB plus IPTG and increasing
amounts of ethyl methane sulfonate (EMS) from 0, 1, 10, 50, 100, and 200
μM. 10 μL aliquots of culture (diluted in 300 μl LB) were plated out on
LB agar plus ampicillin plates and grown overnight at 37C. The next day
10 plates were analyzed for cell viability as determined by colony formation.
Analysis found that while no significant difference in colony number was
observed between the pT7-PMS134 and control at the 0, 1, or 10 uM
concentrations (all had > 1000 colonies), the number of control cells were
reduced to 30 and 0 at the 50 and 100 μM concentrations, respectively. No
15 difference was observed in the pT7-PMS134 cells treated with 0, 1, 10 or
50 μM, while a 3 fold reduction was observed in cultures treated with 100
μM EMS. The 200 μM treatment was toxic for both lines. These data
demonstrate the ability of MMR deficiency to protect prokaryotes against
the toxic effects of DNA alkylating agents and provides a means to generate
20 a wider range of mutations that can lead to an increased number of genetic
variations and an increase in the number of new biochemical activities
within host proteins to produce new output traits for commercial
applications.

- To confirm that MMR deficient bacterial cells treated with CM can
25 result in an increased mutation rate and produce a greater number of
variants, we cultured pT7-PMS134 cells and empty vector controls in the
presence of IPTG for 48 hours, followed by dilution and regrowth in 25μM
EMS for 24 hours as described above. Cells were plated out on 100 mM
petri dishes containing ampicillin or KAN and scored for KAN resistance.
30 Analysis revealed that an 11-fold increase in the generation of KAN

resistant cells were found in pT7-Ea-PMS134V5 cells in contrast to control cells.

- These data demonstrate the use of employing a regulated dominant negative MMR system plus chemical mutagens to produce enhanced numbers of genetically altered prokaryotic strains that can be selected for new output traits. This methods is now useful generating such organisms for commercial applications such as but not limited to recombinant manufacturing, biotransformation, and altered biochemicals (biotransformation) with enhanced activities for manufacturing purposes and gene discovery for pharmaceutical compound development.

EXAMPLE 6: Alternative Methods to Inhibition of Bacterial MMR Activity

- The inhibition of MMR activity in a host organism can be achieved by introducing a dominant negative allele as shown in EXAMPLES 2 and 3. This application also teaches us the use of using regulated systems to control MMR in prokaryotes to generate genetic diversity and output traits for commercial applications. Other ways to regulate the suppression of MMR activity of a host is by using genetic recombination to knock out alleles of a MMR gene that can be spliced out such after selection using a system such as the CRE-Lox system; 2) blocking MMR protein dimerization with other subunits (which is required for activity) by the introduction of polypeptides or antibodies into the host via transfection methods routinely used by those skilled in the art; or 3) decreasing the expression of a MMR gene using anti-sense oligonucleotides.

- MMR gene knockouts. We intend to generate disrupted targeting vectors of a particular MMR gene and introduce it into the genome of bacteria using methods standard in the art. Bacteria exhibiting hypermutability will be useful to produce genetically diverse offspring for commercial applications.

- Bacteria will be confirmed to have lost the expression of the MMR gene using standard northern and biochemical techniques (as described in reference 32). MMR gene loci can be knocked out, strains selected for new output traits and MMR restored by introducing a wildtype MMR gene to complement the KO locus. Other strategies include using KO vectors that can target a MMR gene locus, select for host output traits and then have the KO vector "spliced" from the genome after strain generation. This process could be performed using systems such as but not limited to CRE-Lox.
- 10 Blocking peptides. MMR subunits (MutS and MutL proteins) interact to form active MMR complexes. Peptides are able to specifically inhibit the binding of two proteins by competitive inhibition. The use of peptides or antibodies to conserved domains of a particular MMR gene can be introduced into prokaryotic cells using lipid transfer methods that are
- 15 standard in the art. Bacteria will be confirmed to have lost the expression of the MMR gene using standard northern and biochemical techniques (as described in reference 32). Bacteria exhibiting hypermutability will be useful to produce genetically diverse sibs for commercial applications.

20 Discussion

- The results described above will lead to several conclusions. The expression of dominant negative MMR proteins results in an increase in hypermutability in bacteria. This activity is due to the inhibition of MMR biochemical activity in these hosts. This method provides a claim for use of
- 25 dominant negative MMR genes and their encoded products for the creation of hypermutable bacteria to produce new output traits for commercial applications.

EXAMPLES OF MMR GENES AND ENCODED POLYPEPTIDES

Yeast MLH1 cDNA (accession number U07187)

5
 1 aaatagaagt gtgataccct ctattgcagt caaagatagt gttaggagcgt ctgctattgc
 61 caaagacttt tgagaccttt tgcctgtttc ttatagtgtg ggagttctcg aagacgagaa
 121 attagcagtt tctgggtgtt agtaactcgc ctgacatgct agggcaattt aactgcacaa
 181 tttagatagc atagtgtatg taagtggag gttaaataaa catagacctt tcaataagca
 241 atgtctctca gaataaagc acttgatgca tcaagtggtt acaaaattcg tgcaggtgag
 10
 301 atcataatat cccccgtaaa tgccttcaaa gaaatgatgg agaattccat cgatgcgaat
 361 gctcacaatg ttgatattct agtcaaggaa ggaggaaatt aggtacttca aatacgaat
 421 aacgcatctg gaattaatca agcagacctg ccaattctat gtgagcgatt cacagagctc
 481 aatttcaaaa aattcagaga tttagagagc attcaaaagt atgagtctcg aggaagaagt
 541 tttagcagta tctcacatgt gccaagaatc acagttaacg caaaagttaa agaagacaga
 601 tgtgcatgga gagtttcatg tgcagaaggt aagatgttgg aaagcccaaa acctgttgc
 15
 661 ggaaagagcg gtacacagat cctagtgtga gaccttttt tcaatatccc tcttagatta
 721 aggcctctga ggtccacata tgatgaatcc tctaaaattt tagatgttgc cggcgagctg
 781 gcatctcatt ccaagpacat tgcttttctc tctaaaagt tccgagacct taattattct
 841 ttatcagttt aaccttctta tacaagtcag gatagattta ggactgtgtt caataaattc
 901 gtgcctctga atttattac ttctcatc agcaaatgag aagattttaa cctggaaagc
 961 gttgtagtaa aggtgtgtat tttagattc atattcaaaa agtccatttc atttattttt
 1021 tctcttaata atagatagt gacntgtgtt ctctcaagaa gaggtttgaa caggtttac
 1081 tccaattatc tgcacaaagg cttagacctt ttattttt ttgggaattgt tatagatcgc
 1141 cgcgctgttg atgttaacct taccacgaca aagagagagg ttgctttctt gagccaagt
 1201 gagatcatag agaaatcgc caatcaattg cagcccgcat tatctgcatc tgactcttca
 1261 cgtacttcca aggtcttctc aatttcaaaa acaacggcgc agtcatctgt aactattaat
 1321 gacacatag aagtgatag gaataggaag agtcttcgac aggcacaggt gtagagagat
 1381 tcatataga cagccaatag tcaactaagg aaagcgaaaa gaccaagaga taactagtc
 1441 aagatagtag ctccacaagg taaaatttgc tcatttttat cctcaagtica acagtccaac
 1501 ttggaagatg cgtctacaaa cgaacaactg agtgaaccca aggttaacaa tttaagccac
 1561 tcccaagatg cagaaaagat gaaactaact caaagcgaat cagccgtgca tgcacata
 1621 atcaatgata atgacttgaa ggaataacct aagaagaac aaaaagtggg gatttatata
 1681 gttccaagca ttgcgcgatg cgaagaagat gcaactccga ttccaagaa cgggttatat
 1741 agagtacctt agagcgaggt taatgttat cttagagta tcaagaattt cgcgtgaaaa
 1801 gtatgagat cgatacatgt agaaataaca gcaattttg caaatttga taactgtgag
 1861 gttgtgatgt aggaagaag attagcgctt attcagatg acttaagctt ttatttata
 1921 gattacgagt ctgtgtgcta tgaactatc tatcagatt gtttgacga cttagcaac
 1981 ttgttgtaaa taacctaca gagtacaaat gtgtcagatg atatgttt ttgataatct
 2041 ctatcagat ttgacagatt aaatgacat gtttccaaag aaaaataat tatgtaataa
 2101 tgggcagata cgagtatgct aaatgagtc ttttccatg aattgtgaaa tgaagtctta
 2161 gataatgact taagctctgt gaagctaaaa tctctaccac tacttttaa aggtcatct
 2221 caactctcgg tcaagtacc atttttata tatcgctggt gtaaaaggt tgaatggag
 2281 gatgaacaa agtgtctaga tggatttta agagagattg cctactctca tatecctgat
 2341 atgtttccga aagtcgatac acttcgtgca ctgtgtcag aagacgaaa agccagatt
 2401 ataatataga aggaacatat atcttcatc ctgaacacg tctcttccc ttgtatcaaa
 2461 cgaaggttcc tggcccttag accattctc aagatgtcg tggaaatagc caacttcca
 2521 gatctataca aagtttttga gaggtgttaa cttaaaacg tttgtgctt aatccaaa
 2581 tttttgttta tttctcaggt gtgattgtgt tcatbtgaa agtgatagct atttctctta
 2641 acgattcttc cgcagattt caaagatat gaaataggt tgcagtagg aaagtatct
 15
 2701 agaaatgat attcgagatt aaactttct aatgtctcg aagtcactgt gtctcattt
 2761 gttttgtccc tcttctcaa gcaacgattc ttgtctaac ttattcaac gtaccaaga
 2821 cccagatctt ttatgagag aaacatttc atcattttc aactcaatta tcttaetct
 2881 attttgagt attttgaaa cagatgtgta aaacgactca cctgaactca gaaagtctac
 2941 ctgttcccat aagattttt atttactgaa cctttcgttc aagtaacta gtttatctg
 15
 3001 ttttgaaacg aattattgtg gcagatttgc agtaagtcca gtttagatca ctaaaagtgt
 3061 tttagacaga gccgattcca caaaaattg taaaagag agtaagaga cctcgccgt
 3121 atggtttgac atcaccatgt gatgttgtt gaaaactca ctttttgat ggaagtatt
 3181 aacataaga ctaatgatta ccttagata atgtata

60 Yeast MLH1 protein (accession number U07187)

MSLR1KALDASVVK1AGE11ISPVNALKEMHENS1DANATHI

65 D1LVKEGG1KVLQ1TDNGSG1NKAD1P1LCERFTTS1KLOKFDLS01QTYGFRGALA
 S1SHVARVTVTTRVKEDRCAMRVSYAEGRKLES1PKFVAGKDGTT1ILVDF1FN1PSRL
 70 RALRSHNDYYSK1LVGGVYA1HSKD1GFSCKKFGDSNYLSVKFSYTVQDR1RTVN
 KSVASNL1TFH1SKVEDLNLESVDGKVNLFN1SKS1S1L1FFNNRLVTCDLRRAL
 NSVYSN1PKGFRFP1YLC1VIDPA1VDVNVN1PTKREVRFLS0E11E1KANQLHAEL
 SAIDTSRTFKASS1STNKPES1L1FNDT1ESDRNKS1LRQAQVENS1YTANSQLRKA

KRQENKLVRIASQAKITSFLSSSQOFNEGSSTKROLSEPKYTVNVSQEAELTLN
 5 ESEQPRDANTINDMLDKQPKKQKLDYKVPSTADDEKNALPKSDGYIRPKERVN
 VNLTSIKKLREKVDESIHLRETDIFANLNVYGVVDEERLAAIQHDLKLFDYGSVC
 10 YELFTYQICGLTDFANFGKINLQSTNVSDI VLYNLLSEFDELNDASKEKIIISKIDMS
 SMLNEYYYSIELVNDGLNDLMSVKLSFLPLKGYIPSLVKLPFFIYRLGREVDWEDE
 QECLDGILREIALLYIPMWKPVVDLADLSADEKAQFINRKEHSILLENVLPCKI
 15 RRFLAPRHILKDVVEIANLPDLYKVFRC

Mouse PMS2 protein
 MEQTEGVSTE CAKAIKPIDG KSVHQCISGQ VILSLSTAVK ELIENSVDAG ATTIDRLRLD 60
 YGVDLIEVDH HECGVEEENF EGIALKHNTS KIQEFADLTQ VETFGFGEA LSLCALSDV 120
 TISTCHGASV VGTSLVFDHN GKITOKTYPF RFKGTTSVSQ HLYFTLFPVY KEFORNIKKE 180
 20 YSRMVQVLOA YCIIISAGVRV SCTNLQGGK RHAVVCTSGT SMKENIGSV FGQKQLQSLI 240
 PFVQLPFSDA VCEEYGLSTS GRHKTFSTR ASFHSARTAP GGWQGTGSFS SSIRGPVYQQ 300
 RSLSLSMRFY HMYNRHOYFF VYLVNVSVDSE CVDINVTPOK RQILLCEEKL LLAVLKTSLI 360
 GNFDSDANKL NVHQQPLLED EGNLVKLHTA ELEKPPVPGKQ DNSPSLKSTA DEKRVASISR 420
 LREAFSLWPT KEIKSRGPET AELTRSPFSE KRGVLSSYPS DVISYRGLNG SQDKLVSPTD 480
 25 SPGDCKMUREK IEKDSGLSST SAGEEEFST PEVASSFSD YNVSSLEDRP SQTINCGDL 540
 DCRPPGTGSKS LKPEDHGYOC KALPLARLSF THAKRFKTEE RPSWNVISOR LFGPOSTSAA 600
 EVDVAIKMKN RIVLLEFSLS SIARKMKQLQ HLKAKNQKHEL SYRFRKAKIC PGEHQAAEDE 660
 LRKEISKSMF AEMELGGFN LGFTVTKLKE DLFLVDQNAH DEKNYFEMLQ QHTVLQARLL 720
 ITPQTIANLTA VNEAVLIENL EIFRKNGFDF VIDEFAPYTE RAKLISLPTS KNWTFGQDI 780
 30 DELIFMLSDS PGVHCRPSRV RQMFASRACR KSMVIGTALN ASEMKLITH MGEHDKFWNC 840
 PHGRPTMRHV ANLDVISON
 859

Mouse PMS2 cDNA
 35 gaattccgggt gaaggctcctg aagaatttcc agattccctga gtatcatctg aggagacaga 60
 taacctgtctg tcaggtaacg atggtgtata tgcaacacgaa atgggtgttc ctggagacgc 120
 gtctttttccc gagaagcgga ccgaactctt cccggcggtga ctgtgactgg aggaagtctg 180
 catccatgga gcaaacccgaa ggcgtgagta cagaatgtgc taaggccatc aagcctattg 240
 atgggaagtc agtccatcaa atttgttctg ggcagggtgat actcagttta agcacgcgtg 300
 40 tgaaggagtt gatagaaat agtgtagatg ctggtgctac tactattgat ctaaggctta 360
 aagaactatgg ggtgacacct attgaagttt cagacaatgg atgtggggtg gaagaagaaa 420
 accttgaagg tctagctctg aaacatcaca catctaagat tcaagagttt gccgacctca 480
 cgcagggtga aactttcggc tttcgggggg aagctctgag ctctctgtgt gcaactaagt 540
 atgtcactat atctacctgc caccgggtctg caagcgttgg gactcgactg gtgtttgacc 600
 45 ataattggaa aatcacccag aaaaactcctt acccccagacc taagaagacc acagtcaagt 660
 tgcagcaactt attttatata ctaccctgcg gttacaaaga gtttcagagg aacattaaaa 720
 aggaagtatt caaaatgggt caggtcttac agcgtactgt tatcatctca gcaggcgctc 780
 gtgtaaagctg cactaatcag ctccagcagg ggaagcggca cgctgtggtg tgcacaagcg 840
 gcacgtctgg catgaagaaa aatatcgggt ctgtgtttgg ccagaagcag ttgcaaaagc 900
 50 tcatctcttt ttttcacgtg cccctcagtg acgctgtgtg tgaagagtac ggcctgaagc 960
 ctccagcagg ccacaaaacc ttittctacgt ttcgggcttc atttcacagt gcacgcacgg 1020
 cgccgggaag agtgcacag acagcgagtt ttcttctatc aatcagaagg cctgtgaccc 1080
 agcaaaagtc tctaagcttg tcaatgagtg ttatcatcac gtataacggc catcagttacc 1140
 catcttgctg ccttaacggt tccgttgact cagatgtgtg ggatattaat gtaacttcag 1200
 55 ataaaaggca aattctacta caaagaagaa agctatttgc ggccgtttta aagacctctt 1260
 tgtagaagat gtttgacagt gatgcaaaa agcttaagtgt caaccagcag ccactgctag 1320

atgttggaagg taacttagta aagctgcata ctgcagaact agaaaagcct gtgccaggaa 1380
 agcaagataa ctctcttcta ctgaagagca cagcagcaga gaaaaggta gcatccatct 1440
 ccaggctgag agaggccttt tctcttcac ctactaaga gatcaagctc aggggtccag 1500
 5 agactcgtga actgacacgg agttttccaa gtgagaaaaa gggcgtgtta tctcttacc 1560
 ctccagactg catctcttca agaggcctcc gtgctctgca ggacaaattg gtgagttccca 1620
 cggacagccc tgggtactgt atggacagag aaaaataga aaagactca ggcctcagca 1680
 gcacctcagc tggctctgag aaagagttca gaaccaccga agtgccactg agctttagca 1740
 gtgactataa cgtgagctcc ctagaagaca gaccttctca gaaaaccata aactgtggtg 1800
 acctggactg cgtctctcca ggtacaggac agtctctgaa gccacaagac catggatata 1860
 10 aatgcaaaagc tctacttcta gctcgtctgt caccacaaa tgccaagcgc ttcaagacag 1920
 aggaagaagcc ctcaaatgct aacatttctc aaagattgct tggctctcag agcaactcag 1980
 cagctgaggt cgtatgagcc ataaaaatga ataaagaaat cgtgctcttc gacttctctc 2040
 tgaattctct agctaagcga atgaagcagt tacagacact aaaggcgcag acaaaacatg 2100
 acctgagttt cagaaaaatt agggccaaaga ttgctctgga agaaaacca gacgacaga 2160
 15 atgaactcag aaaaagagatt agtaaatcga tggttgcaga gatggagatc ttgggtcagt 2220
 ttaacctggg attttagta accaaactga aagaggacct ctctctggtg gaccagcatg 2280
 ctgcggatga gaagtacaac ttgagatgc tgcagacaga caccgtgctc caggccgaga 2340
 ggctcctcag acccagact ctgaacttaa ctgctgtcaa tgaagctgta ctgatagaaa 2400
 atctggaat attcagaag aatggcttgg actttgcat tgaatgagat gctccagcca 2460
 20 ctgaaggggc taaattgatt tctttaccaa ctagtataaa ctgagacctt ggaccccaag 2520
 atatagatga actgatcttt atgttaagt acagccctgg ggtcatgtgc cggccctcac 2580
 gactcagaca gatgttggct tccagagcct gtgggaagtc agtcatgatt ggaacggcgc 2640
 tcaatgcgag cgaatgaag aagctcatca cccacatggg tgagatggac caccctgga 2700
 actgccccca cggcagacca accatgagggc agcttgccaa tctggtatgc atctctcaga 2760
 25 actgacacac ccttctgagc atagagttaa ttacagattg tctggttgc aaagagaaag 2820
 ttitaagtaa tctgattac gttgtacaaa aattagcatg ctgctttaa gtactgtatc 2880
 catttaaaag cagtgttaag gcaggcatag tggagtgttc ctctagctca gctacttggg 2940
 tgatccgggt ggagctcatg tgagcccgag actttgagac cactccgagc cacattcatg 3000
 30 agactcaatt caagacaaa aaaaaaaga tattttgaa gccctttaaa aaaaaa 3056

human PMS2 protein
 MKQLFAATYR LLSSSQIITS VVSUVKELIE NSLDAGATSV DVKLENYGFD KIEVRDNGEG 60
 IKAVDAPVMA MKYITSKINS HEDLEHLTTY GFRGEALGSI CCIAEVLIIT RTAADNFSTQ 120
 35 YVLDGSGHIL SQKPSHLOOG TTVTALRLFK NLPVRQFQYS TARKCKDEIK KIQDLMSFG 180
 ILKPDRLRIV VHNKAVIWK SRVSDHKQAL MSVLGTAVMN NMESFOYHSE LSQIYLSGFL 240
 VKCDADHSFT SLSTPERSFI FINSRPVHQK DILKLIRHY NLCKLESTR LYEVFFLKID 300
 PPTADVDVNL TPQKSOVILQ NKESVLJALE NLMTTCYGLF PSTNSYENNK TVDAAIDVL 360
 SKTAETDVLV NKVESSGQNY SNVDSVIPF QNDMHNDESG KNTDCLNHQ ISIGDFGYGH 420
 CSSEISNIDK NTKNAFQDIS MSNVSWSQSO TEYSKTCFIS SVKHTQSENG NKDHIDESGE 480
 40 HEEAGLENS SEISADENSR GNILKNSVGE NIEPVKILVF EKSLPCKVSN NRYPIPEQMN 540
 LNEDSCNKKK NVIDNKGKV TAYDILLSRV IKKPMASALF FVQDHROPFL IENPFTSLSD 600
 ATLQIEELWK TLSEEEKLY EEAATKDLER YNSQMKRAIE QESQMSLKG RKIKPSTSAW 660
 NLAQKHKLKT SLHQPKLDE LLQSOIEKRR SQNIKQVQIF FSHKHLKINF KQKQKVDLEE 720
 KDFCLILHNL RFPDNLWITS RTEVMLLAFY RVEEALLFKR LLENHKLPAE PLEKPIMLTE 780
 45 SLFNGSHYLD VLYKMTADDO RYSGSTYLSO PRLTANGFKI KLIPGVSTIE NYLEIEGMAN 840
 CLPFYGVADL KEILNAILNR NAKVEYECFR RKVISYLEGE AVKLSRQLPM YLSKEDIQOI 900
 IYRMKHQFQN EIKECVHGRF FFRHLTYLFE TT 932

5 Human PMS2 cDNA
 cgaggcggat cgggtttgtc atccatggag cgaactgaga gctcgagtac agaactctgt 60
 aaggccatca aacctattga tcggagagca gtccatcaga ttgtctctgc gcaggttgta 120
 ctgagcttaa gcactgcggt aaagcaatta gtgaaacaca gtctggatgc tgggtgccat 180
 aatattgata taagacttaa ggactatgga gtggatctta ttgaagtctc agacaattga 240
 10 tgtggggtag aagaagaaaa ctctcaagc ttaactctga aacatcacac atctaaagt 300
 caagagtttg ccgacttaac tcaggttgaa acttttggct ttccggggga agctctgagc 360
 tcactttgtg cactgagcga tgcaccattt tctacctgcc acgcatcgcc gaaggttga 420
 actcgactga tgtttgatca caatcggaaa attatccaga aaacccccta cccccgcc 480
 agagggacca cagtcacggt gcagcagtta trttccacac tactgtgctg ccataaggaa 540
 15 ttccaaagga atattaagaa ggagtatgcc aaatggctcc aggtcttaca tgcatactgt 600
 atcatttcag caggcatccg tgaagtgtgc accaatcagc ttggacaagg aaacgacag 660
 ctgttggtat gcacaggtg aagcccacgc ataaagaaa atactggctc tgtgtttggg 720
 cagaagcagt tgcaaagcct cactccittt gtccagctgc cccctagtga ctccgtgtgt 780
 gaagagtacg gtttgagctg ttccgatgct ctgcataact ttttttacat ctccagtttc 840
 20 atttcacat gcacgcagtg agttggaagg agttcaacag acagacagtt tttctttatc 900
 aaccggcgcc ctgtgaccc agcaaaagtc tgcagactcg tgaatgaggt ctaccacatg 960
 tataatgcag accagtatcc atttgttgt cttaacattt ctgttgatcc agaatgcgtt 1020
 gatatcaatg ttactccaga taaaaggcaa attttgtac aaagagaaaa gotttttgtt 1080
 gcagttttaa agactctctt gataggaaat ttgtgatgtg atgtcaacaa gctaaatgct 1140
 25 agtcagcagc cactgctgga tgttgaaggt aacttaataa aaatgcacgc agcggaattg 1200
 gaaaagccca tggtagaaaa gcaggatcaa tccccttcac taaggactgg agaagaaaa 1260
 aaagacgtgt ccatttccag actcgcagag gccctttctc ttctgcacac aaacagaaac 1320
 agccttcaca gcccaaaagc tccagaacca agaaggagcc ctctaggaca gaaaaggggt 1380
 atgtgtcttt cttagcattc aggtgccatt ctgcacaaag gcgtcctgag acctcagaaa 1440
 30 gagcagtgga gttccagta cggaccacgt gacctacag acagagcggg gttggaaga 1500
 gactcggggc acggcagcac ttccgtggat tctgaggggt tcagatccc agacacgggc 1560
 agtcactgca gcagcgagta tgcggccagc tcccacgggg acaggggctc gcaggaacat 1620
 gtggactctc aggagaagc gcctgaaact gacgactctt ttccagatgt ggaactgccat 1680
 tcaaacagg agataccgg atgtataatt cgagttttgc ctacagcaac taacttcgca 1740
 35 accccaaca caaagcgttt taataaagaa gaattcttt cagtttctga catttgcga 1800
 aagttagtaa atactcagga catgcacgc tctcaggttg atgtagctgt gaaaattaat 1860
 gaagaagttg tgcccctgga ctcttctatg agttctttag ctaaaacpat aaagcagtta 1920
 catcatgaag ccacgcaagc tgaaggggaa cagaattaca ggaagtttag ggcaagattt 1980
 tttctctgag aaaaacagc agccgaagat gaactaagaa aagagatag taacacgatg 2040
 40 ttgcagaaa tggaaatcat tggctcagtt aacctggat ttataataac caaactgaat 2100
 gaggatatct tcatagtga cccagctgcc acggacgaga agtataactt cgagatgctg 2160
 gcacgacaca cgtgtctcca ggggcagagg ctcatagcac ctccagactc caacttaact 2220
 gctgttaagt aagctgtctc gatagaanaa ctggaatat ttgaaagaa tggctttgat 2280
 ttttgtatcg atgaaaatgc tccagtaact gaaggggcta aactgatttc cttagcaact 2340
 45 agtaaaaaat ggaacttcgg accccaggac gtccatgaac tgatcttcac gctgagcagc 2400
 agccctgggg tcatgtgccc gccctcccga gtcaagcaga tgtttgcctc cgagacgtgc 2460
 cggaaatcgg tgatgalttg gactgtcttt aacacagcgc agatgaagaa actgatcacc 2520
 cacatgggg agatggacca cccctggaac tgtcccctga gaaggccaac catgagacac 2580
 atcgcaacc tgggtgtcat ttctcagac tgacctgatg cactgtatgg aataattggt 2640

tttatcgag atttttatgt ttgaaagac agagcttca ctaacctttt ttgttttaa 2700
atgaaacctg ctacttaaaa aaatacaca tcaccacct ttaaaagta tcttgagaac 2760
cttttcaaac c
2771

5

human PMS1 protein

10 MPQLPAATVR LLSSQIIITS VVSVKELIE NSLDAGATSV DVKLENYGFD KIEVRNDEG 60
IKAVDAPVMA HKYITSKINS HEDLENIITY GFRGEALGSI CCIAEVLITT RTAADNFSTQ 120
YVLDGSHIL SOKPSHLGGQ TTUTALRLFK NLPVRKQFYS TAKKCKDEIK KIODLLMSFG 180
ILKPDRLIVF VHNKAVIQWR SRVSDHMMAL MSVLGTAVMN NMESFOYHSE ESQIYLSGFL 240
PKCDADHSFT SLSTPERSFI FINSPPVHQK DILKLRHYH NLKCKLESTR LYPVFLLKID 300
VPTADVVNL TPKKSQVLLQ NKESVLIAL E NIMTTCYGLP PSTNSYENNK TDVSAADIVL 360
SKTAETDVLK NKVESGKNY SNVDTSVIFF QNMINDESG KNTDDCLNHQ ISIGDFGYGH 420
15 CSSEISNIDK NTKNAFQDIS MSNVSWNSQ TEYSKTCFIS SVKHTQSENG NKDHIDESGE 480
NEEEAGLENS SEISADEMSR GNILKNSVGE NIEPKILVP EKSLPKVSN NNYPIEQHN 540
LNEDSCNKS NVINCKGKV TAYDLLSNRV IKKPMASAL FVDHPRPFL IENPKTSLD 600
ATLQIEELWK TLSEEEKLY EEKATKDLER YNSQMKRAIE QESQMSLKG RKIKRPTSAW 660
NIAQCKKLKT SLSNQKLDE LLQSQTEKR SQNIKRVQIP FSNKMLKINF KQKNVLDLE 720
20 KDEPCLIHNL RFPDANIMTS KTEVMLLNPY RVEEALLFKR LLENMKLPAE PLEKPIMLTE 780
SIFNGSHYLD VLYKMTADDQ RYSGSTYLSL PRLTANGFKI KLIPGVSITE NYLEIEGMAN 840
CLFPYGVADL KEILNAILNR NAKEVYECRP RKVISYLEGE AVRLSRQLPM YLSKEDIQDI 900
IYRMKHQFGH EIKECVHGRP FPHILTYLPE TT
932

25

Human PMS1 cDNA

ggcagcagtg gctgcttgcg gctagtggat ggtaattgcc tgcctcgcg tagcagcaag 60
ctgctctgtt aaaagcgaaa atgaacaat tgcctcgcg aacagttcga ctctttcaa 120
gtttccagat catcacttgc gtgctcagtg ttgtaaaaga gcttattgaa aactccttgg 180
30 atgctgtgct cacaaagcga gatgttaac tggagaacta tggatttgat aaaattgagg 240
tgcgagataa cggggaaggt atcaaggctg ttgatgcacc tgaatttgca atgaagtact 300
acacctcaaa aataaatagt catgaagatc ttgaaattt gacaacttac ggttttcctg 360
gagaagcctt ggggtcaatt tgttgtagat ctgaggtttt aattacaaca agaagcgctg 420
ctgataattt tagcaccocg tatgttttat atggcagtg ccacatactt tctcanaan 480
35 ettcacatct tggtaaggt acaactglaa ctgctttaag attatttaag aatctacctg 540
taagaagaac gttttactca actgcacaaa aatgtaaga tgaataaaa aagatccaag 600
atctctcat gagcttttgt atctctaaac ctgacttaag gattgtcttt gtacataca 660
aggcagttat ttgcgagaaa agcagagatg cagatcacaa gatggctctt atgtcagtc 720
tggggactgc tgttatgaac aataggaat cttttcagta ccaactcgaa gaattcaga 780
40 ttatctcag tggatttctt ccaagatgtg atgcagacca ctcttcaat agtctttcaa 840
caccagaag aagtttcatc ttcataaaca gtcaccagt acatcaaaaa gatattctaa 900
agttaatccg acatcattac aatctgaaat gcctaaagga atctactcgt ttgtactcgt 960
tttctttct gaataatgat gtctctcag ctgattgtga tgaataatta acaccagata 1020
aaagccaagt attattacaa aataaggaat ctgttttaat tgcctctgaa aatctgtatga 1080
45 cgacttgta tgaaccatta ctagatcaaa atcttatga aaataaaaa acagattgtt 1140
ccgcagctga catcgttctt agtaaaacag caganaacaga tgtgcttttt aataaagtg 1200
aatcatctcg aaagaattat tcaaatgtg atacttcagt cattccattc caaattgata 1260
tgcataatga tgaacttga aaaaacnct atgattgttt aaatccagg ataatgtatg 1320
gtgacttgg ttatgtcat tgtagtatg aaattctcaa cattgtataa aacactaaga 1380

- 41 -

atgcatttca ggcatttca atgagtaatg tatcatggga gaactctcag acggaataata 1440
 gtaaaacttg ttttataagt tccgttaagc acaccacgtc agaaaatgac aataaagacc 1500
 atatagatga gaagtgygaa aatgaggaag aagcaggtct tgaaaactct tcggaataatt 1560
 ctgcagatga gtggagcagg ggaataatc ttaaaaattc agtggagag aatattgac 1620
 5 cttggaataa tttagtgcct gaataaagt taccatgtaa agtaagtaat aataattac 1680
 caatccctga acaaatgaat cttaatgaag attcatgtaa caaaaatca aatgtaatag 1740
 ataataaatt tggaaaagtt acagettatg attacttag caatcgagta atcaagaatac 1800
 ccatgtacag aagtgtcttt ttgttcaag atcattgtcc tcaatttctc atagaaaatac 1860
 ctaagantag tttagaggat gcaacactac aaattgaaga actgtggaag acattgagtgc 1920
 10 aagaggaaaa actgaataat gaagagaagc ctactaaga cttggaacga tcaatagtcc 1980
 aatgaagag agccattgaa caggagtcac aatgtccact aaagatggc agaaaaaaga 2040
 taaaacccca cagcgcattg aatttggccc agaagacaa gttaaaacc tcaattctca 2100
 atcaaccocaa acttgatgaa ctcttcagtt ccaaatliga aaaaagaagg agtcaaaaa 2160
 ttaaaatggt acagatcccc ttttctatga aaaaacttaaa aataaatttt aagaacaaa 2220
 15 acaaatgtga cttgaagaag aaggatgaac cttgcttgat ccaacatctc aggtttctcg 2280
 attgctggct aatgacatcc aaaaacagagg taatgttatt aaatccatat agagtagaag 2340
 agccctctgt atttaaaaaa ctctctgaga atcataaact tctgcagag ccaatggaaa 2400
 agccaattat gttacagag agtcttttta atggatctca ttatttagac gttttatata 2460
 aaatgacagc agatgaccaa agatcacagt gatcaactta cctgtctgat cctgtcttta 2520
 20 cagcgaatgg ttcaagaata aaattgatac caggagtttc aattactgaa aattactgtg 2580
 aatagaagag aatggctaatt tgcctccat tctatggagt agcagattta aaagaatttc 2640
 taatgtctat attaaacaga aatgcaaaag aagtttatga atgtagacct cgcaaaagta 2700
 taagtatttt agaggagaaa gcagtgcctc tatccagaca attaccatg tactatcaaa 2760
 aagaggacat ccaagacatt atctacagaa tgaagacca gtttggaaat gaaattaaa 2820
 25 agtgtgttca tggctgccca ttttttctc atttaacctc tcttcacaga actactgatg 2880
 taastatgtt taagaagatt agttacatt gaatttggtt ctgtcataaa acagcatgatg 2940
 tctgtgttta aattatcttt gtattatgtg tccatgggtt atttttttaa tgaggattca 3000
 ctgacttggt tttatatga aaaaagttcc acgtattgta gaaaactgaa ataaactaat 3060
 aac 3063
 30

human MSH2 protein
 MAVQPRETLQ LESAAEVGFV RFFQGMPEKP TTVRLRFDGR DFYTAGEDA LLAAREVFKT 60
 QGVIKYMGPA GAKNLOSVVL SHMFESFVK DLLLRVQYRV EVYKNRAGNK ASKENDRYLA 120
 35 YKASPGNLSQ FEDILFGNND MSASIGVGVG KMSAVDGRQV VGVCYVDSIQ RKLGLCLFPD 180
 NOQFSNLEAL LIQIGPKFVC LFGGTAGDM GKLRQIQRG GILITERMKA DFSTKDIYQD 240
 LNRLLKKGKK EOMNSAVLPE MENQVAVSSL SAVIKFLELL SDGNSQGFPE LTFDFDSQM 300
 KLDIAAVRAL NLFQGSVEDT TGSQSLAALL NKCKTPQGR LVNQNIKQPL MKNRIEERL 360
 NLVEAFVEDA ELRGTQLEDL LRRFDIARL AKKFRQAAN LQDCYRLYQG INQLPNVIOA 420
 40 LKHEGKHOK LLLAVFVPLT TDLRSDFSKF QEMTETLDM QOVNHEFLV KPSDFPNLSE 480
 LREIMNOLKX KMOSTLSIAA RDLGLDRGK IKLSSAQGF YFRVTCHEE KVLNNKNFS 540
 TVDIQRNGVK FINSKLTSIA EYTKNKTEY EEAQDAIYKE IYNSISGYVE PMQTLNDVLA 600
 QLDVYVSFAH VSNQAPVPYV RPAILENGOG RIILKASHHA CVEODEIAF IPNDVYFEK 660
 KQNFHITGP NMKGKSTYIR QTVGVIMAG IGCFVPCESA EVSIVDCILA RVGAGDSQLK 720
 45 GVSTFAEML ETASILRSAT KDSLIIDEL GRCTSTYDGF GLAWATSEYI ATKIGAFCHF 780
 ATHFHELTAL ANQIFTVNNL NVHTALTEET LTMLYQVKKG VQDSQFGLHV NELANPKHV 840
 IECAGKALE LEEFQYIGES GYDIMEPAK KRCYLREBQG EKIIQFELSK VKQMPFTEHS 900
 EEMITIKLQ LKAEVIAKMN SFVNEIISRI KVTI 934

Human MSH2 cDNA

ggcgggaac agcttagtg gtgtgggtc ggcattttc ttcaaccagg aggtgaggag 60
 gtttcgacat ggcgggtcag ccgaagpaga cgtctgagtt ggagagcgcg gccgaggtcg 120
 gcttcgtcgc cttctttcag ggcagtcgag agaagccgac caccacagtg gcccttttcg 180
 5 accggggcga cttctatcag gcgcagcgcg aggaagcgct gctggccgce cgggaggggtg 240
 tcaagaccga ggggggtgac aagtaacatg gccggcagag acaaaagaat ctgcagagtg 300
 ttgtgcttag taaatgaat tttaactctt ttgtaaaaga tctctttctg gttcgtcagt 360
 atagagttga agttttaaag aatagaagctg gaaataaagg atccaaggag aatgattgtg 420
 atttggcata taaggctctt cctggcaatc tctctcagtt tgaagacatt cttcttggtg 480
 10 acaatgatat gtcagcttcc attgtgtgtg tgggtgttaa aatgtccgca gttgatggcc 540
 agagacaggt tggagtgtgg tatgtggatt ccatacagag gaactagga ctgtgtgaat 600
 tccctgataa tgactgctc tccaactctg aggccttctc catccagatt ggaccaaaag 660
 aatgtgtttt accggaggga gagactgctg gagacatgag gaactcagga cagataaatt 720
 aaagggaggg aattctgac acagaaagaa aaaagagctga cttttccaca aagacattt 780
 15 atcaggacct caaccgggtg ttgaaagcca aaaagggaga gcagatgaat agtgcgtgat 840
 tgccagaagt ggagaatcag gttgcagttt catcactgtc tggcgttaac aagtttttag 900
 aactcttacc agatgatccc aactttggac agtttgaaat gactactttt gaecttagcc 960
 agtatatgaa attgataatt gcagcagtcg gagcccttaa cttttttcag ggtctgtgtg 1020
 aagataccac tgcctctcag tctctgctcg cctgtgctga taagtgtaaa acccctcaag 1080
 20 gacaaagact tgttaaccag tggataaagc agcctctcat gataaagac aagatagagg 1140
 agagattgaa tttagtggaa gcttttttag aagatgcaga attgaggcag actttcaag 1200
 aagatttact tctgtgattc ccagatctta accgacttgc caagaagttt caaagacaga 1260
 cagcaaaactt acaagattgt taccgactct atcagggtat aaatcaacta cctaattgta 1320
 tacaggctct ggaaaaaact gaaggaaaac accgaagatt attgttggca gttttttgtg 1380
 25 cttctcttacc tgatcttctg tctgacttct ccaagtttca ggaaatgata gaaacaattt 1440
 tagatatgga tcaggtggaa aaccatgaat tctttgtaaa accctcaatt gatctaatc 1500
 tcagtgaatt aagagaataa atgaatgaat tggaaaagaa gatgcagtcg acattataa 1560
 gtgcagccag agatcttggc ttggaacctg gcaaacagat taaactggat tccagtgcac 1620
 agtttggata ttactttctg gtaacctgta aggaagaataa agtcttctgt acaataaasa 1680
 30 actttagtag ttagatatac cagaagaatg gtgttaattt taccacagc aaattgactt 1740
 ctttaaatga agatataacc aaaaataaaa cagaatatga agaagccagc gatgccattg 1800
 ttaagaatatt tgcataattt tcttcaggct atgtagaacc aatgcagaca ctcaatgatg 1860
 tttaagaaat gctagatgct gttgtcagct ttgtctcagc gtcaaatgga gccactgttc 1920
 tttagactca gctagatgct gttgtcagct ttgtctcagc gtcaaatgga gccactgttc 1980
 35 catatgtacg accagccatt ttggagaag gacaaggaag aattatataa aaagcatcca 2040
 ggcatgctgt tgttgaagtt caagatgaaa ttgcatttat tctaatgac gtatactttg 2100
 aaaaagataa acagatgttc cacatcatta ctggcccaca tatgggaggt aaatcaactt 2160
 atattcagca aactgggggtg atagtactca tggcccacaa ttgggtgttt gtgccatgtg 2220
 agtcagcaga agtgtccatt gtgactgca tcttagcccg agtaggggct ggtgcagctg 2280
 40 aattgaaagg agtctccacg tcatgtgtg aaatgttgg aactgcttct atctcaggt 2340
 ctgcacccaa agattcatta ataactcag atgaattggg aagaggaact tctactcag 2400
 atggaatttg gttagcatgg gctatctcag aatcacttgc acaaaagatt ggtgcttttt 2460
 gcatgtttgc acccatttt catgaactta ctgecttggc caatcagata coaactgtta 2520
 ataacttaca tgtcacagca ctcacactgt aagagacctt aactactgct tatcaggtga 2580
 45 aagaagggtg ctgtgatcaa agttttggga tctatgttgc agagcttgc aatttcccta 2640
 agcatgtaat agagtgtgct aaacagaag ccttgggaact tgaggagttt cagtatatgt 2700
 gagaatcgca agatgatgat atcatggaa cagcagcaaa gaagtgcata ctggaagaag 2760
 cgcgaaggtga aaaaattatt caggagtctt gtcccagggt gaacaaatg ccccttactg 2820
 aaatgtcaga agaaaacttc acaataaagt taaaacagct aaaagctgaa gtaatagca 2880
 aagaataaag cttttgtaat gaaatcattt caggaataaa agttactacg tgaaaaatcc 2940

cagtaattgga atgaaggttaa tattgataag ctattgtctg taatagtttt atattgtttt 2940
 atattaaccc tttttccata gtgttaactg tcagtgccca tgggcatca acttaataag 3000
 atatttagta atattttact tggaggacat ttccaagat tttttatttg aaaaatgaga 3060
 gctgttaactg aggaactgttt gcaattgaca taggcaataa taagtgtgt gctgaatttt 3120
 5 ataaataaaa tcatgtagtt tgtgg
 3145
 human MLH1 protein
 MSFVAGVIR LDETYYNRIA AGEVIQRPN AIKEMIENCL DAKSTSIQVI VKEGGLKLIQ 60
 10 IUNGDTGIRK EDDLIVCFER TTSKLQSTED LASISTYFGR GEAALASISV ARVITTTTKTA 120
 DGKCAFRASY SDGKLKAPFK PCAGHGQGTI TVEDLFYNIA TRKALKNPS EYEGKILEVY 180
 GRYSVHRHAGI SFSVKKQGET VADVRLPNA STVDNIRISIF GNAVSRELIE IGCEDKTLAF 240
 RMNGVISNAN YSVKRCIFLL FINHRLVEST SLRKALETYV AAYLPKNTHP FLVLSLEISP 300
 QNVUYNVHPT KREVHFLHEE SILERVQOHI ESKLLGSNS RHVFTQTLLP GLAGPSGEMV 360
 15 KSTTSLTSSS TSGSSDMKYA HQNVKTSRE QKLDAPLQL SKPLSSQPOA IVTEKTDIS 420
 SGRAPQDESE MLELPAPAEV AAKNQSLQED TTKTSEMSE KRGPTSSNPR KHRREDSQVE 480
 MVEDDSRKEM TAACTPRRRI INILSVLSLQ EEINBQGEV LREHLNHSF VGCVPNQWAL 540
 AQHQTKLYLL NTKTLSEELF YQILLYDFAN FGVLRLSEPA FLFDLAMLAL DSPESGWTEE 600
 DPKREGIAEY IVEFLKKKAE MLADYFSLEI DEGNLIGLP LLIDNYVFPPL EGLFIFILRL 660
 20 ATEVNVHDEK ECFESLSKEC AMFYSIKQY ISEESTLSGQ QSEVPGSIPN SWKNTVEHIV 720
 YKALRSILP PKHFTKDGNI LQLAHLFDLY KVPERC 756
 Human MLH1 cDNA
 cttagctctt ctggcgccaa aatgtcgttc gtggcagggg ttattcggcg gctggcagcg 60
 25 acagtggtga accgcctcgc ggcgggggaa gttatccagc ggcagcgtaa tgcatacaaa 120
 gagatgattg agaactgttt agatgcataa tccacaagta ttcaagtgtat tgttaaaagag 180
 ggagggcctga agttgatcca gatcccaagc aatggcagcg ggaacaggaa aagaagatctg 240
 gatattgtat gtgaaagggt cactactagt aaactgcagt ccttgaggaa ttiagccagt 300
 atttctacct atggctttcg agtgaggct ttggcagcca taagccatgt ggctcatgtt 360
 30 actattacaa cgaaacacgc tgatggaagc tgrgcataca gacacagtaa ctccagatgga 420
 aaactgaaag cccctccata accatgtgct ggcaatcaag ggaaccagat cagcgtggag 480
 gacctttttt acaacatagc caagcaggaa aaagtcttaa aaaaaccaag tgaagaatat 540
 gggaataatt tggaaagttg ttgcaggtat tcagtcacaa atgcaggcat taatttctca 600
 gtaaaaaaac aaggagagac agtagctgat gttagcaaac tacccaatgc ctcaacgctg 660
 35 gacaatttc gtccatcttt tggaaatgct gttagtcgag aactgataga aattgagatt 720
 gaggataaaa ccttagcctt caaaatgaat ggttacatat ccaatgcasa ctaactcagt 780
 aagaagtcca tcttctact ctccatcaac catcgctctg tagaatcaac ttccttgaga 840
 aaagccatag aaacagcta tgcagcctat ttgcccaaaa acacacaccc attcctgtac 900
 ctcaagttaa aaatcagctc ccagaatgtg gatgttaag tgcacccac aaagcatgaa 960
 40 gtccacttcc tgcacaggaa gacatcctg gacgggtgac agcagcacat cgagagcaag 1020
 ttcctgggct ccaattcttc caggatgtac ttcaccgaca ctttctacc aggaactgtc 1080
 ggccccctct ggagatggt taaatccaca acaagtctga cctcgtcttc tactcttggg 1140
 agtagtgata agtctatgc ccacagatg gtctgtacag attcccgagg acagaagctt 1200
 gatgcatctc tgcagcctc gagcaacccc ctgtccagtc agccccaggc cattgtcaca 1260
 45 ggagataaga cagatatctc tagtggcagg gctaggcagc aagatgagga gatgcttggg 1320
 ctccccagcc ctgctgaagt ggctgccaaa aatcagagct tggagggggg tacaacaaa 1380
 ggaacttcag aaagtgcaga gaagagagga cctacttcca gcaacccag aaagagacat 1440
 cggaagatt ctgatggga aatggtggaa gatgattccc gaagagaaat gactgcagct 1500
 tgtaccccc gggaagagat cattaacccc actagtgttt taagtctcca ggaagaaat 1560

aatgagcagg gacatgaggt tctccgggag atgttgcata accactcctt cgtgggctgt 1620
 gtgaatccctc agtgggcctt ggcacagcat caaaccaagt tataccttct caaacaccac 1680
 aagcttagtg aagaactgtt ctaccagata ctcatattat attttgccaa ttttggtgtt 1740
 ctcaagttat cggagccagc accgctcttt gaccttgcca tggctgctt agatagttca 1800
 gagagtggct ggacagagga agatggtccc aaagaaggac ttgctgaata cattgttgag 1860
 5 tttctgaaga agaaggtgga gatgcttgca gactatttct ctttggaat tgatgaggaa 1920
 gggaacctga ttgatttacc cttctgatt gacaactatg tggccctttt ggaaggactg 1980
 cctatctcca ttcttcgact agccactgag gtgaattggg acgaagaaaa ggaatgtttt 2040
 gaaagcctca gtaaaagatg cgtattgttc tattccatcc ggaagcagta catatctgag 2100
 10 gagtgcaccc tctcagccca gcagagtga gtcgctggct ccatctcaaa ctctggaag 2160
 tggacttggg aacacattgt ctataaagcc ttgcgctcac acattctgcc tcttaaacat 2220
 ttacagaag atggaatat cctgcaagct gctaactctg ctgactcata caaagtcttt 2280
 gagaggtgtt aaatatgttt atttatgac tgtgggatgt gtcttcttt ctctgtattc 2340
 cgatacaag tttgtatca aagtgatga tacaaagtgt accaacataa gtgttgtag 2400
 15 cacttaagac ttatacttg cttctgtag tattcttita tacacagtgt attgattata 2460
 aataaataga tgtgtcttaa cata 2484

hPMS2-134 protein
 MKQLPAATVR LLSSQIIIS VVSVVKELIE NSLDAGATSV DVKLENYGFD KIEVRNGEG 60
 20 IKAVDAPVMA NKYYTSKINS HEDLENLTYY GFRGEALGSI CCIAEVLIT RTAADNFSTQ 120
 YVLDSGHIL SQK 133

hPMS2-134 cDNA
 cgaagcggat cgggtgttgc atccatggag cgagctgaga gctcgagtag agaacctgct 60
 25 aaggccatca aacctattga tcggaagcca gtccatcaga ttgtctctgg cgaggttgta 120
 ctgagcttaa gcactcggtt aaaggagtta gtagaataca gctcggatgc tggcgccact 180
 aatattgata taaagcttaa ggaactatga gtggatctta ttgaagtttc agacaatgga 240
 tgtggggtag aagaagaaaa ctctgaagcc ttaactctga aacatcacac attctaagatt 300
 caagagtttg ccgacctaac tcaggttgaa acttttggct ttccggggga agctctgagc 360
 30 tcactttgtg cactgaagca tgtcaacatt tctactgcc acgcatcgcc gaaagttgga 420
 acttga 426

hMSH6 (human cDNA) ACCESSION U28946
 35 MSRQSTLYSFFPKSPALSDANKASARASREGGAAAA PGASPS
 GGDAAWSEAGPGPKPLARSASPPKARNLNGLLRRSVA PAATSCDFS PGDLVWAHMEG
 40 YPMPCLVYVNHFDGTFIREKGSVRVHVQFFDOSPTRGMVSKRLKPYTGSKSEAK
 KGGHFYSAPKEILRAMORADEALNKDKIKRLAVCDPSEPEEEENEVGTYYVTDK
 SEEDNEIESEEVQPKTQGSRRSSRIKKRRVISDSSESIGGSDVEFKPDTKEGSSD
 45 EISSGVCDSEGLNHPVKARKKRWITGNGSLKRSKRPTSATKQATSISSETK
 NTLRAFSA PQNSESQAHSVGGGDDSSRPTVYWHETLWLEKKRDEHRRRDPHDFD
 50 ASTLYVPEDFLNSCTPGMRKWKQIKSONFDLVI CYKVGKFEYLYHMDALIGVSELGLV
 FMKNWHAHSGPEIAFGRYSDSLVOKYKVARVEQTETPEHMEARCRQMAHISKYDRV
 VRREICRIJTKGTOTYSVLEGGDSENYSKVLLSKEEEDSSGHTRAYGVCFVDTSLG
 55 KFFIQTGSDDRHCRSFRTLVAVYPPVOVLFKGNLSKETKTI LKSSLSCLSQGLIPG
 SQFWADSKTLRTLLLEEFYFKELSDGIVMLPQVLKMTSESISGLTPGEKSELALS
 60 ALGGCVIYLLKCLIDQELLSMANFEYIPLSDTVSTTRSGATFKAYQWVLDVATL
 NNLEIPLNGTNGSTEGTLLRWITCHYPTGRLLKQWLKAPLCNHAIINDRLDAIEDL

5 MYVPEKISEVVELLKKGLDLEERLLSKHNWGSPLKSGMHDSRAHYEETTSYKKKII
 DFLSALEGFVKMCKIIGIMEEVAOGFKSKILKQVISLQTKNPEGRFDLTVELNRNDT
 10 AFDHEKARKTGLITPKAGFDSYDQDLADIRENOSLLEYLKRQRIRGTCRTIYVWG
 GRNRYCLEIFENFTTRILPEEYELKSTKGGCKRYMTKIERKKLANLHAEERDVSLEK
 DCMRRLFTYHDKNYKQWQSAVECIADVLDLCLANTYSGGDDGRCRVPILLFEDTPPF
 15 LELKGRSHFCTITFTGDDFTNDILIGCEEEEOENGKAYCVLVTGNNGGKSTIMHO
 AGLLAVMAHQMCYVPEVCFRLTIDRVITRLGASDRINSGESTFVLESETASIMHA
 TASHLVLDLGRGTATFDGTAIANAVKLEAETIKRCTLSTHYHSLVEDYSQNVAV
 20 RLGHMACMVNECEDPSQETITFLYKFIKGACPKSYGFNARLANLPEEVIQNGHRA
 REFEMNOSLRLEFREVCLASERSTVDEAEVHKLLTLIKEL"

hFMSR2 (human cDNA) ACCESSION U38964

25 1 ggcgtacta cctgcaagtg gctagtcca agtgcctggc cgcgcctct cgcgtcagt
 61 ttgggagcc agtacctgc gtgggctcc acaggaag ggcgcagc cgtgtacag
 121 ggccttacct ggtactcgt catggcgcaa ccaagcaag agaagtggtg cgtgccaga
 181 caccacaggt cggaaaccgc cagacaccaa cgttcgaaa cgcaccaag ccaacgctc
 241 ggaacacgc agacaccaa gctcggaac cgcagacac caagctcgg aatcacgcgc
 301 aggcacagc gaggagcag taccctcct ctgacacgc tgcgtgcgt cggaaaaaac
 361 gcagtcctgt gtgctctgat tggctcaggc tctttgacct cagcgaatc acccttgaca
 421 ggcgactag cgaaaaaga gagacggaa gtatttttc cgcgccccc gaaaaggtg
 481 gagcacaac tcgaaacag cgttggag cccagaggg cgggcgcctg tggagcgtg
 541 ggaaggaaat ttcccagtc cccagggcga tccgtgttg catccttga cgcagctgag
 35 601 aactcgagt cagaacctg taagggcct aaactatg atcggaatc agtccatcag
 661 atttgctctg gcccgttgt accgaatc atggcgaatg cgtggaagga gttagtaga
 721 aacagctcgt atgctgtg cactaatgt gatcaaac taaaggacta tggagtggat
 781 ctcatctgaa ttccagcaa tggatgtgg gtagaaga aactctga aggtcttact
 841 ctgaacatc acactgaa tgaatgaag ttgcgacc taactcaggt ggaactctt
 40 901 ggccttcagg ggaagctct gagctcact tggcgaatc catctctacc
 961 tgcctgtgat cagcgaagt tggactga cttggtttg atcactatg gaaactctc
 1021 cagaaaaacc cctaccccc cccagaggg atgacatga cgtgaagca gttattttc
 1081 acgtacctg tgcaccata agaatttcaa agaatatta agaaagaac tgcctgtctc
 1141 cctctcgtc tctgcgtga ttgctggt ttgcagcgt cccagagcat gctctcga
 45 1201 cagcctgtag aactgactc tagaagta ccaaccacc cctgctctt ggaagacaac
 1261 gtgactcgt tattcagctc tgcagaat ggtccaggt cttctagatg atctgcaca
 1321 atgttctc tctcctctc tgatgtgc cattaagatt ggaataaagt tctctctgaa
 1381 aatcaaaaa aaaaaaaa aaaaaaa

hFMSR2 (human protein) ACCESSION U38964

55 MAOPKQERVARARHORSETARHORSETAKTFTILGNRFTILGNR
 QTPRLGIHARFRRATTSLTLTLAFGKNVRCALIGRGLSTRPLTEFLGKERR
 EVFFPPRPERVEHNVSSRWEPRRRGACSGRGNFSPRGGSGVASLEKANSSTFA
 60 KAKLPIDRKSVOICSGPPVSLPRNAVLEKVLNSLDAGATNVDLKLKDYGVDLIEVS
 GNCGVVEENFEFGTLKHHTKIQEADLTQVETFGFNGEALSSLCALSDVITSTRV
 SAKVGTSLVFDHYGKIIQNTFYPRFGHTVSVKQLFSTLPVHHKEQRNKKRACFP
 65 FAFRCDCQFPEASPAMLPVQVFLTPRSTPEHPCSLSDNVITVFSVKNPGSGSR

HPMSR3 (human cDNA) ACCESSION U38979

70 1 tttttagaaa ctgatgttta ttttccata accatttttc catgctgctt aagaagaat
 61 gcaagaacag cttagaacca gtcatgtgtt gctctacc attcagtgcc ctgagcagtg
 121 ggaagctgca gaccagtctt cctggcag ctgagcgtc cagtcttcag tagggaattg
 181 ctgaatagc acagaggga cctgtacac ttcaagccag tctgaacct caggtcgtg
 241 agcagtgac tcaggaggg gagcagcca ttccacctg aattctctt tggctcagc
 301 cttctcagca gcagctgct cttcttttc aatcttcca ggtctctgt aagaatcag
 361 atcaggcatg acctcccatg ggtgttccg ggaatgggt ccaagcatgc cgaagaactc
 421 ccgagccagc atccaccaca ttaaacccac tgggtgact cctgtgtgt tgcattggat
 481 ggaatgtccc acatagcga gaggagaatc tgtgttacc agcgaatg tggtaggtt

541 aacataagat gccctccgtga gaggcgaaag ggcgcgcgga cccgggctg gcccgctatg
 601 gtcccttgag gccctagacta ggcctctgct gtatggtgag ccccgaggag gccgatctgg
 661 gcccccagaa ggaacccgc ctgatttgc cccatgccc gccccggccc cctcgggagc
 721 agaacagcct tggtaggttg gacaggagag gacctcgaga gcaagcgcgc gccgcagcga
 781 gcaagagccc gcccgagct ctcggagccc gggggcgaga ggtcgccgag ccccgaggag
 841 gctctatcgc cacagtctct gcatgtttcc aagagcaaca ggaatgaac acattgcagg
 901 ggccagtgct attcaaatg atgtgctgtg atttaccaca ggaagagtg gcgcgaactg
 961 accctgatga gaagatagca tacggggatg tgafttga gaactacagc catctagttt
 1021 ctgtggggtg tgatataca caagccaaa atcatcatg agtggagtg aagaaagtgt
 1081 agcaagagga gggcgtgtg ataatggaag gtgaatttcc atgtcaaat atgtcagac
 1141 ctgctaaagc catcaaacct attgatcgga agtcagtcga tcaagtttgc tctgggcccag
 1201 tggtagtgag tctaaagact gaagtgaag agttagtag aaacagtcty gatctggtg
 1261 ccaactaatat tgatctaaag cttaaggact atggaatga tctcatgaa gttcagaca
 1321 atggatgtg gtagaaga gaaactttg aagcttaat ctctttcag tctgaacct
 1381 caccatgta agttcaaga gtttccgac ctaactgaag ttgaacctt cgttttcag
 1441 ggggaagctc tgagctact ctgtgactg agcgatgca ccaatttcc atgcgcagc
 1501 ttggtgaag ttgagactc actggtgtt gatcacgat ggaataact ccaagaaac
 1561 cctaccccc accccagag gaccacagc agcgtgaac agttttcc tacyctact
 1621 gtcgcata aggaattcc aagbatatt aagaagact gctgcttcc ccttcgctt
 1681 ctgcctgat tgcctatc ctgagccct cccagcatg ctctctgtac agctcgaga
 1741 actgtgagtc aattaacct ctittcttca taattaaaa aaaaa

25 hPMSR3 (human protein) ACCESSION U38979

MCWPRLGRRCVSPREADLPGQKTRLDLPSRPARPREQNS

30 LGVEVDRGPREQTRAFATAAPFRLGSRGAARAEQGLSATVSACFOEQEEMHTLGG

PVSFKDVAVDFTEQRQLDPEKIAYGDMLENYSILVSVGYDHYQAKHHIGVEVKE

VEQGEPEWIMEGEFFQCHSPFAKAIKIDRSVHQICSGPVVLSLSTAVKLVENSL

35 DAGATNIDLKLDYGVLLIEVSDNGCQVEENFGLISFSSETSHM*

hPMSL9 (human cDNA) ACCESSION NM_005395

40 1 atgtgtccct ggccgacctg actagccgtt cgtgtatgg tgaeccccag gggaggcagat
 61 ctggggccccc agaaagacac ccgcctggat ttgccccta gcccgcccc ggccctcgg
 121 gacagagaca gcccttggtga ggtgacagg agggagctc gcgagcagac gcgcgcgcca
 181 gcgacagcag ccccgcccgc gccctctcgg agccgggggg caagagctgc ggagcccag
 241 gaggtgttat cagccacagt ctctcatgt ttccaaagc aacaggaat gaacacattg
 301 caggggccag tgcatttcaa agatgtgct cggagttcca ccaaggaga gtggcgcca
 361 ctggaccctg atgagaagt agctatcgg gatgtgatg tgaagaacta cagcatctca
 421 gttctctggt ggtatgatta tcaccaagcc aaacatcatc atggagtgga ttgaaggaa
 481 gttggagcag gagagagcgt gtggataat gaagtgat ttccatgtca acatagttca
 541 gaactctcta aggccatcaa acctattgat cgaagctcag tccatcagat ttgctctgg
 601 ccaagtgttc tgaactaag cactgcagt aaggagttg tagaatacau tctgatgct
 661 gtcgcacta atattgatct aaagcttaag gactatgag tgaattcat tgaatttca
 721 gcaaatgat gtggggtaga aagaataaac ttgaagctt taattcttt cagctctgaa
 781 acatcacca tgtaa

55 hPMSL9 (human protein) ACCESSION NM_005395

MCWPRLGRRCVSPREADLPGQKTRLDLPSRPARPREQNS

60 LGVEVDRGPREQTRAFATAAPFRLGSRGAARAEQGLSATVSACFOEQEEMHTLGG

PVSFKDVAVDFTEQRQLDPEKIAYGDMLENYSILVSVGYDHYQAKHHIGVEVKE

65 VEQGEPEWIMEGEFFQCHSPFAKAIKIDRSVHQICSGPVVLSLSTAVKLVENSL

DAGATNIDLKLDYGVLLIEVSDNGCQVEENFGLISFSSETSHM*

References

1. Attfield, P.V. and Pinney, R.J. 1985. Elimination of multicopy plasmid R6K by bleomycin. *Antimicrob. Agents Chemother.* 27(6):985-988.
- 5 2. Baker S.M., Bronner, C.E., Zhang, L., Plug, A.W., Robatez, M., Warren, G., Elliott, E.A., Yu, J., Ashley, T., Arnheim, N., Bradley, N., Flavell, R.A., and Liskay, R.M. 1995. Male defective in the DNA mismatch repair gene PMS2 exhibit abnormal chromosome synapsis in meiosis. *Cell* 82:309-319.
- 10 3. Berry, A. 1996. Improving production of aromatic compounds in *Escherichia coli* by metabolic engineering. *Trends Biotechnol.* 14(7):250-256.
- 15 4. Bronner, C.E., Baker, S.M., Morrison, P.T., Warren, G., Smith, L.G., Lescoe, M.K., Kane, M., Earabino, C., Lipford, J., Lindblom, A., Tannergard, P., Bollag, R.J., Godwin, A., R., Ward, D.C., Nordenskjold, M., Fishel, R., Kolodner, R., and Liskay, R.M. 1994. Mutation in the DNA mismatch repair gene homologue *hMLH1* is associated with hereditary
20 non-polyposis colon cancer. *Nature* 368:258-261.
- 25 5. de Wind N., Dekker, M., Berns, A., Radman, M., and Riele, H.T. 1995. Inactivation of the mouse *Msh2* gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. *Cell* 82:321-300.
6. Drummond, J.T., Li, G.M., Longley, M.J., and Modrich, P. 1995. Isolation of an hMSH2-p160 heterodimer that restores mismatch repair to tumor cells. *Science* 268:1909-1912.

30

7. Drummond, J.T., Anthoney, A., Brown, R., and Modrich, P. 1996. Cisplatin and adriamycin resistance are associated with MutLa and mismatch repair deficiency in an ovarian tumor cell line. *J.Biol.Chem.* 271:9645-19648.
8. Edelmann, W., Cohen, P.E., Kane, M., Lau, K., Morrow, B., Bennett, S., Umar, A., Kunkel, T., Cattoretti, G., Chagnatti, R., Pollard, J.W., Kolodner, R.D., and Kucherlapati, R. 1996. Meiotic pachytene arrest in MLH1-deficient mice. *Cell* 85:1125-1134.
9. Fishel, R., Lescote, M., Rao, M.R.S., Copeland, N.J., Jenkins, N.A., Garber, J., Kane, M., and Kolodner, R. 1993. The human mutator gene homolog *MSH2* and its association with hereditary nonpolyposis colon cancer. *Cell* 7:1027-1038.
10. Fu, K.P., Grace, M.E., Hsiao, C.L., and Hung, P.P. 1988. Elimination of antibiotic-resistant plasmids by quinolone antibiotics. *Chemotherapy* 34(5):415-418.
11. Leach, F.S., Nicolaides, N.C., Papadopoulos, N., Liu, B., Jen, J., Parsons, R., Peltomaki, P., Sistonen, P., Aaltonen, L.A., Nystrom-Lahti, M., Guan, X.Y., Zhang, J., Meltzer, P.S., Yu, J.W., Kao, F.T., Chen, D.J., Cersaletti, K.M., Fournier, R.E.K., Todd, S., Lewis, T., Leach R.J., Naylor, S.L., Weissenbach, J., Mecklin, J.P., Jarvinen, J.A., Petersen, G.M., Hamilton, S.R., Green, J., Jass, J., Watson, P., Lynch, H.T., Trent, J.M., de la Chapelle, A., Kinzler, K.W., and Vogelstein, B. 1993. Mutations of a *mutS* homolog in hereditary non-polyposis colorectal cancer. *Cell* 75:1215-1225.

12. Li, G.-M., and Modrich, P. 1995. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human mutL homologs. *Proc. Natl. Acad. Sci. USA* 92:1950-1954.
- 5
13. Liu, B., Parsons, R., Papadopoulos, N., Nicolaides, N.C., Lynch, H.T., Watson, P., Jass, J.R., Dunlop, M., Wyllie, A., Peltomaki, P., de la Chapelle, A., Hamilton, S.R., Vogelstein, B., and Kinzler, K.W. 1996. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. *Nat. Med.* 2:169-174.
- 10
14. Modrich, P. 1994. Mismatch repair, genetic stability, and cancer. *Science* 266:1959-1960.
- 15
15. Nicolaides, N.C., Gualdi, R., Casadevall, C., Manzella, L., and Calabretta, B. 1991. Positive autoregulation of *c-myc* expression via MYB binding in the 5' flanking region of the human *c-myc* gene. *Mol. Cell. Biol.* 11:6166-6176.
- 20
16. Nicolaides, N.C., Correa, I., Casadevall, C., Travali, S., Soprano, K.J., and Calabretta, B. 1992. The Jun family members, c-JUN and JUND, transactivate the human *c-myc* promoter via an Apl like element. *J. Biol. Chem.* 267, 19665-19672.
- 25
17. Nicolaides, N.C., Papadopoulos, N., Liu, B., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M., de la Chapelle, A., Vogelstein, B., and kinzler, K.W. 1994. Mutations of two PMS homologs in hereditary nonpolyposis colon cancer. *Nature* 371: 75-80.
- 30

18. Nicolaides N.C., Kinzler, K.W., and Vogelstein, B. 1995. Analysis of the 5' region of PMS2 reveals heterogenous transcripts and a novel overlapping gene. *Genomics* 29:329-334.
- 5
19. Nicolaides, N.C., Carter, K.C., Shell, B.K., Papadopoulos, N., Vogelstein, B., and Kinzler, K.W. 1995. Genomic organization of the human PMS2 gene family. *Genomics* 30:195-206.
- 10
20. Nicolaides, N.C., Palombo, F., Kinzler, K.W., Vogelstein, B., and Jiricny, J. 1996. Molecular cloning of the N-terminus of GTBP. *Genomics* 31:395-397.
21. Palombo, F., Hughes, M., Jiricny, J., Truong, O., Hsuan, J. 1994. Mismatch repair and cancer. *Nature* 36:417.
- 15
22. Palombo, F., Gallinari, P., Iaccarino, I., Lettieri, T., Hughes, M.A., Truong, O., Hsuan, J.J., and Jiricny, J. 1995. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. *Science* 268:1912-1914.
- 20
23. Pang, Q., Prolla, T.A., and Liskay, R.M. 1997. Functional domains of the *Saccharomyces cerevisiae* Mhl1p and Pms1p DNA mismatch repair proteins and their relevance to human hereditary nonpolyposis colorectal cancer-associated mutations. *Mol. Cell. Biol.* 17:4465-4473.
- 25
24. Papadopoulos, N., Nicolaides, N.C., Wei, Y.F., Carter, K.C., Ruben, S.M., Rosen, C.A., Haseltine, W.A., Fleischmann, R.D., Fraser, C.M., Adams, M.D., Venter, C.J., Dunlop, M.G., Hamilton, S.R., Petersen, G.M., de la Chapelle, A., Vogelstein, B., and kinzler, K.W. 1994. Mutation of a
- 30

- mutL homolog is associated with hereditary colon cancer. *Science* 263:1625-1629.
25. Parsons, R., Li, G.M., Longley, M.J., Fang, W.H., Papadopolous, N.,
5 Jen, J., de la Chapelle, A., Kinzler, K.W., Vogelstein, B., and Modrich, P.
1993. Hypermutability and mismatch repair deficiency in RER⁺ tumor
cells. *Cell* 75:1227-1236.
26. Parsons, R., Li, G.M., Longley, M., Modrich, P., Liu, B., Berk, T.,
10 Hamilton, S.R., Kinzler, K.W., and Vogelstein, B. 1995. Mismatch repair
deficiency in phenotypically normal human cells. *Science* 268:738-740.
27. Perucho, M. 1996. Cancer of the microsatellite mutator phenotype.
Biol Chem. 377:675-684.
- 15 28. Prolla, T.A., Pang, Q., Alani, E., Kolodner, R.A., and Liskay, R.M.
1994. MLH1, PMS1, and MSH2 Interaction during the initiation of DNA
mismatch repair in yeast. *Science* 264:1091-1093.
- 20 29. Strand, M., Prolla, T.A., Liskay, R.M., and Petes, T.D. Destabilization
of tracts of simple repetitive DNA in yeast by mutations affecting DNA
mismatch repair. 1993. *Nature* 365:274-276.
30. Studier, F.W. Use of bacteriophage T7 lysozyme to improve an
25 inducible T7 expression system. 1991. *J. Mol. Biol.* 219(1):37-44.
31. Su, S.S., Lahue, R.S., Au, K.G., and Modrich, P. 1988. Mismatch
specificity of methyl directed DNA mismatch corrections in vitro. *J. Biol.*
Chem. 263:6829-6835.

32. Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B 1998. A naturally occurring hPMS2 mutation can confer a dominant negative mutator phenotype. *Mol Cell Biol* 18:1635-1641.
33. Aronshtam A, Marinus MG. 1996. Dominant negative mutator mutations in the mutL gene of *Escherichia coli*. *Nucleic Acids Res* 24:2498-2504.
34. Wu TH, Marinus MG. 1994. Dominant negative mutator mutations in the mutS gene of *Escherichia coli*. *J Bacteriol* 176:5393-400.
35. Brosh RM Jr, Matson SW. 1995. Mutations in motif II of *Escherichia coli* DNA helicase II render the enzyme nonfunctional in both mismatch repair and excision repair with differential effects on the unwinding reaction. *J Bacteriol* 177:5612-5621.
36. Studamire B, Quach T, Alani, E. 1998. *Saccharomyces cerevisiae* Msh2p and Msh6p ATPase activities are both required during mismatch repair. *Mol Cell Biol* 18:7590-7601.
37. Alani E, Sokolsky T, Studamire B, Miret JJ, Lahue RS. 1997. Genetic and biochemical analysis of Msh2p-Msh6p: role of ATP hydrolysis and Msh2p-Msh6p subunit interactions in mismatch base pair recognition. *Mol Cell Biol* 17:2436-2447.
38. Lipkin SM, Wang V, Jacoby R, Banerjee-Basu S, Baxevanis AD, Lynch HT, Elliott RM, and Collins FS. 2000. MLH3: a DNA mismatch repair gene associated with mammalian microsatellite instability. *Nat Genet* 24:27-35.
39. Lee CC, Lin HK, Lin JK. 1994. A reverse mutagenicity assay for alkylating agents based on a point mutation in the beta-lactamase gene at the active site serine codon. *Mutagenesis* 9:401-405.
40. Vidal A, Abril N, Pueyo C. 1995. DNA repair by Ogt alkyltransferase influences EMS mutational specificity. *Carcinogenesis* 16:817-821.
41. Fu, K.P., Grace, M.E., Hsiao, C.L., and Hung, P.P. 1988. Elimination of antibiotic-resistant plasmids by quinolone antibiotics. *Chem. Abstracts* 34(5):415-418.
42. BiWang, H., ZhiPeng, H., and Xiong, G. 1999. Transformation of *Escherichia coli* and *Bacillus thuringiensis* and their plasmid curing by

electroporation. J. of Fujian Agricultural University 28(1):43-46.

- 5 43. Brosius, J. 1988. Expression vectors employing lambda-, trp-, lac-,
and lpp-derived promoters. Biotechnology 10:205-225.

WE CLAIM:

1. A method for making a hypermutable bacteria, comprising the step of:
introducing into a bacterium a polynucleotide comprising a dominant
- 5 negative allele of a mismatch repair gene under the control of an inducible
transcription regulatory sequence, whereby the cell becomes inducibly
hypermutable.
2. The method of claim 1 wherein the mismatch repair gene is MutH from
any species.
- 10 3. The method of claim 1 wherein the mismatch repair gene is a MutS
homolog from any species.
4. The method of claim 1 wherein the mismatch repair gene is a MutL
homolog from any species.
5. The method of claim 1 wherein the mismatch repair gene is a MutY
- 15 homolog from any species.
6. The method of claim 1 wherein the mismatch repair gene is *PMS2*.
7. The method of claim 1 wherein the mismatch repair gene is plant *PMS2*.
8. The method of claim 1 wherein the mismatch repair gene is *MLH1*.
9. The method of claim 1 wherein the mismatch repair gene is *MLH3*.
- 20 10. The method of claim 1 wherein the mismatch repair gene is *MSH2*.
11. The method of claim 1 wherein the mismatch repair gene is a *PMSR* or
PMSL homolog.
12. The method of claim 3 wherein the allele comprises a truncation
mutation.
- 25 13. The method of claim 4 where the allele comprises a truncation
mutation.
14. The method of claim 6 where the allele comprises a truncation
mutation.
15. The method of claim 7 where the allele comprises a truncation
- 30 mutation.

16. The method of claim 4 wherein the allele comprises a truncation mutation at codon 134.
17. The method of claim 6 wherein the allele comprises a truncation mutation at codon 134.
- 5 18. A homogeneous composition of cultured, hypermutable, bacteria which comprise a dominant negative allele of a mismatch repair gene under the control of an inducible transcriptional regulatory sequence.
19. The homogeneous composition of claim 18 wherein the mismatch repair gene is a mutL gene or a homolog thereof.
- 10 20. The homogeneous composition of claim 18 wherein the mismatch repair gene is *PMS2* or a homolog thereof.
21. The homogeneous composition of claim 18 wherein the mismatch repair gene is *MLH1* or a homolog thereof.
22. The homogeneous composition of claim 18 wherein the mismatch repair gene is *PMSR* or a *PMSR* homolog.
- 15 23. The homogeneous composition of claim 18 wherein the mismatch repair gene is mutS or a homolog thereof.
24. The homogeneous composition of claim 18 wherein the mismatch repair gene is eukaryotic.
- 20 25. The homogeneous composition of claim 18 wherein the mismatch repair gene is prokaryotic.
26. The homogeneous composition of claim 20 wherein the bacteria comprise a protein which consists of the first 133 amino acids of PMS2.
27. The homogeneous composition of claim 26 wherein the protein is human PMS2.
- 25 28. The homogeneous composition of claim 23 comprising a mammalian MutS protein.
29. The homogeneous composition of claim 19 comprising a mammalian MutL protein.

30

30. The homogeneous composition of claim 19 comprising a eukaryotic MutL protein.
31. The homogeneous composition of claim 23 comprising a protein which consists of a eucaryotic MutS protein.
32. A method for generating a mutation in a gene of interest comprising the steps of:
- growing a bacterial culture comprising the gene of interest and a dominant negative allele of a mismatch repair gene under the control of an inducible transcriptional regulatory sequence, wherein the cell is hypermutable;
 - testing the cell to determine whether the gene of interest harbors a mutation.
33. The method of claim 32 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
34. The method of claim 32 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
35. The method of claim 32 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
36. The method of claim 32 wherein the step of testing comprises analyzing a phenotype associated with the gene of interest.
37. The method of claim 32 wherein bacteria in the bacterial culture are made by the process of introducing a polynucleotide comprising a dominant negative allele of a mismatch repair gene into a bacterium, whereby the cell becomes hypermutable.
38. The method of claim 37 wherein the step of testing comprises analyzing the nucleotide sequence from the gene of interest.
39. The method of claim 37 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.

40. The method of claim 37 wherein the step of testing comprises analyzing a phenotype associated with the gene of interest.
41. A method for generating a mutation in a gene of interest comprising the steps of:
- 5 growing a bacterium comprising the gene of interest and a dominant negative allele of a mismatch repair gene under the transcriptional control of an inducible regulatory sequence to form a population of mutated bacteria;
- cultivating the population of mutated bacteria under trait selection
- 10 conditions; and
- testing at least one of the cultivated bacteria to determine whether the gene of interest harbors a mutation.
42. The method of claim 41 wherein the step of testing comprises analyzing a nucleotide sequence of the gene of interest.
- 15 43. The method of claim 41 wherein the step of testing comprises analyzing mRNA transcribed from the gene of interest.
44. The method of claim 41 wherein the step of testing comprises analyzing a protein encoded by the gene of interest.
45. The method of claim 41 wherein the step of testing comprises
- 20 analyzing a phenotype associated with the gene of interest.
46. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to manufacture a protein produced by said bacteria and harvesting the protein therefrom.
- 25 47. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to biotransform a substrate.
48. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to
- 30 bioremediate.

49. The method of claim 41 wherein the gene of interest is an antibiotic resistance determinant and further comprising the step of comparing the genome of the cultivated bacteria harboring a mutation in the antibiotic resistance determinant to a genome of a corresponding wild type strain, thereby identifying the gene of interest.
50. The method of claim 41 further comprising the step of growing a cultivated bacteria harboring a mutation in the gene of interest to screen effects of a compound library.
51. A method for enhancing the mutation rate of a bacterium, comprising the steps of:
- exposing a bacterium comprising a dominant negative allele of an MMR gene to a mutagen whereby the mutation rate of the bacterium is enhanced in excess of the rate in the absence of mutagen and in excess of the rate in the absence of the dominant negative allele.
52. The method of claim 51 wherein the mutagen is a chemical mutagenic agent.
53. The method of claim 51 wherein the mutagen is a DNA alkylating agent.
54. The method of claim 51 wherein the mutagen is a DNA intercalating agent.
55. The method of claim 51 wherein the mutagen is a DNA oxidizing agent.
56. The method of claim 51 wherein the mutagen is ionizing radiation.
57. The method of claim 51 wherein the chemical mutagen is ultraviolet radiation.
58. A method for generating an MMR-proficient bacterium with a new output trait, comprising:
- growing a mismatch repair deficient bacterium comprising a defective mismatch repair gene allele and a gene of interest, to form a population of mutated bacteria;

- cultivating the population of mutated bacteria under trait selection conditions;
- testing at least one of the cultivated bacteria to determine that the gene of interest harbors a mutation; and
- 5 restoring mismatch repair activity to the at least one cultivated bacteria.
59. The method of claim 58 wherein the mismatch repair deficient bacterium comprises a dominant negative allele of a mismatch repair gene.
60. The method of claim 59 where in the step of restoring MMR activity
- 10 comprises removing an inducer chemical that positively regulates the dominant negative MMR allele's expression.
61. The method of claim 59 where in the step of restoring MMR activity comprises excising the dominant negative gene by recombination.
62. The method of claim 59 where in the step of restoring MMR activity
- 15 comprises knocking out the MMR dominant negative gene allele.
63. The method of claim 59 where in the step of restoring MMR activity comprises negatively selecting for loss of the dominant negative allele from bacterial host.
64. The method of claim 58 wherein the mismatch repair deficient
- 20 bacterium is treated with a mutagen to enhance the rate of mutation.
65. The method of claim 58 wherein the mismatch repair deficient bacterium is treated with a chemical mutagen to enhance the rate of mutation.
66. The method of claim 58 wherein the mismatch repair deficient
- 25 bacterium is treated with ionizing radiation to enhance the rate of mutation.
67. The method of claim 58 wherein the mismatch repair deficient bacterium is treated with ultraviolet (UV) irradiation to enhance the rate of mutation.

68. The method of claim 58 wherein the step of restoring MMR activity comprises complementing with a wild-type MMR allele.
69. The method of claim 51 wherein the dominant negative allele is under the control of an inducible promoter.
- 5 70. The method of claim 58 wherein the dominant negative allele is under the control of an inducible promoter.




FIGURE 1.

Western blot analysis of IPTG-induced DH10B bacteria expressing the empty vector (lane 1) or hPMS134 dominant negative gene (lane 2). Lysates from bacteria were loaded onto SDS-PAGE gels and probed with an antibody against the human PMS2 N-terminus.

2/6




Figure 2.
Western blot of PMSI34V5 and PMSR3V5 in IPTG-treated (+) and untreated (-) samples in BL21 bacteria.
Blots were probed with an anti-V5 antibody which is directed to the C-terminal tag of each protein.

PMS134 Expressing bacteria produce KAN^r phenotype




Figure 3. Number of Kanamycin Resistant PMS134 and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

PMS134 and PMSR3 expressing bacteria produce KAN^r phenotype




Figure 4. Number of Kanamycin resistant PMS134, PMSR3 and vector control BL21 clones. IPTG-induced strains were grown and plated onto KAN plates and grown for 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.




Figure 5. (A) Western blot of steady-state ATPMS134flag in IPTG-treated samples in DH10B bacteria. Lysates from control cells (lane 1) and a bacterial clone expressing the *Arabidopsis thaliana* PMS134 truncated protein with a FLAG epitope fused to the C-terminus (ATPMS134flag) (lane 2) were electrophoresed on SDS-PAGE gels. Blots were probed with an anti-FLAG monoclonal antibody directed to the FLAG epitope. (B) Number of Kanamycin Resistant ATPMS134flag and vector control DH10B clones. IPTG-induced strains were grown and plated onto AMP and KAN plates and grown for an additional 18 hours at 37°C to identify number of KAN resistant clones due to genetic alteration.

6/6




Figure 6.

Generation of high recombinant producer BGAL-MOR lines in PMS134 expressing DH5alpha host strains. DH5alpha cells containing pTLACZ and TACLACPMS134 were grown with (+) or without (-) IPTG and plated onto LB-Xgal-agar plates. Arrow indicates clones containing pTLACZ and TACLACPMS134 with enhanced β -galactosidase levels *in situ*.